







Quality of Care for Adults in Medicaid: Findings from the 2020 Adult Core Set

Chart Pack

January 2022

This chart pack is a product of the Technical Assistance and Analytic Support for the Medicaid and CHIP Quality Measurement and Improvement Program, sponsored by the Center for Medicaid and CHIP Services. The technical assistance team is led by Mathematica, in collaboration with the National Committee for Quality Assurance, Center for Health Care Strategies, AcademyHealth, and Aurrera Health Group.

Table of Contents

ABOUT THE FFY 2020 ADULT CORE SET	6
OVERVIEW OF STATE REPORTING OF THE 2020 ADULT CORE SET	7
Number of Adult Core Set Measures Reported by States, FFY 2020	8
Number of States Reporting the Adult Core Set Measures, FFY 2020	9
Number of States Reporting the Adult Core Set Measures, FFY 2018–FFY 2020	10
Geographic Variation in the Number of Adult Core Set Measures Reported by States, FFY 2020	12
Populations Included in Frequently Reported Adult Core Set Measures for FFY 2020, By Domain	13
Median Performance Rates on Frequently Reported Adult Core Set Measures, FFY 2020, By Domain	15
PRIMARY CARE ACCESS AND PREVENTIVE CARE	20
Breast Cancer Screening	21
Cervical Cancer Screening	23
Chlamydia Screening in Women Ages 21 to 24	25
Adult Body Mass Index Assessment	27
Flu Vaccinations for Adults Ages 18 to 64	29



Table of Contents (continued)

MATERNAL AND PERINATAL HEALTH	31
Prenatal and Postpartum Care: Postpartum Care	32
Contraceptive Care: Postpartum Women Ages 21 to 44	34
Contraceptive Care: All Women Ages 21 to 44	39
CARE OF ACUTE AND CHRONIC CONDITIONS	42
Comprehensive Diabetes Care: Hemoglobin A1c (HbA1c) Poor Control (>9.0%)	43
PQI 01: Diabetes Short-Term Complications Admission Rate	45
PQI 05: Chronic Obstructive Pulmonary Disease (COPD) or Asthma in Older Adults Admission Rate	47
PQI 08: Heart Failure Admission Rate	49
PQI 15: Asthma in Younger Adults Admission Rate	51
Plan All-Cause Readmissions	53
Asthma Medication Ratio: Ages 19 to 64	55
Controlling High Blood Pressure	59



Table of Contents (continued)

BEHAVIORAL HEALTH CARE	61
Use of Opioids at High Dosage in Persons Without Cancer	62
Concurrent Use of Opioids and Benzodiazepines	64
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment	66
Medical Assistance With Smoking and Tobacco Use Cessation	75
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or	
<u>Dependence</u>	79
Follow-Up After Emergency Department Visit for Mental Illness	82
Follow-Up After Hospitalization for Mental Illness: Age 18 and Older	85
Antidepressant Medication Management	88
Adherence to Antipsychotic Medications for Individuals with Schizophrenia	91
Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications	93
LONG-TERM SERVICES & SUPPORTS	95
National Core Indicators Survey	96



Table of Contents (continued)

TRENDS IN STATE PERFORMANCE, FFY 2018–FFY 2020	100
Trends in State Performance, FFY 2018–FFY 2020: Introduction	101
Trends in State Performance, FFY 2018–FFY 2020: Primary Care Access and Preventive Care	102
Trends in State Performance, FFY 2018–FFY 2020: Maternal and Perinatal Health	103
Trends in State Performance, FFY 2018–FFY 2020: Care of Acute and Chronic Conditions	104
Trends in State Performance, FFY 2018–FFY 2020: Behavioral Health Care	106
REFERENCE TABLES AND ADDITIONAL RESOURCES	108
Overview of State Reporting of the Adult Core Set Measures, FFY 2020	109
Performance Rates on Frequently Reported Adult Core Set Measures, FFY 2020	112
Trends in Performance Rates on Frequently Reported Adult Core Set Measures, FFY 2018–FFY 2020.	118
Acronyms	121
Additional Resources	123



About the FFY 2020 Adult Core Set

Medicaid plays an important role in health care coverage for adults, covering almost 47 million adults in federal fiscal year (FFY) 2020, including over 28 million non-disabled adults under age 65, 11 million non-elderly with disabilities, and 6 million adults age 65 and older. As the U.S. Department of Health & Human Services agency responsible for ensuring quality health care coverage for Medicaid beneficiaries, the Centers for Medicare & Medicaid Services (CMS) plays a key role in promoting quality health care for adults in Medicaid. CMS's 2020 core set of health care quality measures for adults covered by Medicaid (referred to as the Adult Core Set) supports federal and state efforts to collect, report, and use a standardized set of measures to drive improvement in the quality of care provided to Medicaid beneficiaries. The 2020 Adult Core Set includes 33 measures.

This Chart Pack summarizes state reporting on the quality of health care furnished to adults covered by Medicaid during FFY 2020, which generally covers care delivered in calendar year 2019. The Chart Pack includes detailed analysis of state performance on 28 publicly reported measures.³ For a measure to be publicly reported, data must be provided to CMS by at least 25 states and meet CMS standards for data quality. These measures address the following domains of care:

- Primary Care Access and Preventive Care
- Maternal and Perinatal Health
- Care of Acute and Chronic Conditions
- Behavioral Health Care
- Long-Term Services & Supports

More information about the Adult Core Set, including measure-specific tables, is available at https://www.medicaid.gov/medicaid/quality-of-care/performance-measurement/adult-and-child-health-care-quality-measures/adult-health-care-quality-measures/index.html.

measures that address key aspects of health care access and quality for adults covered by Medicaid



¹ Medicaid enrollment data for FFY 2020 is available at https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/CMS-Fast-Facts/index.html.


² Two measures were retired from the 2020 Adult Core Set and two measures were added. Information about the updates to the 2020 Core Sets is available at https://www.medicaid.gov/federal-policy-guidance/downloads/cib111919.pdf.

³ The count of 28 publicly reported measures includes the Consumer Assessment of Healthcare Providers and Systems (CAHPS) measure. State-specific performance data are not available for this measure.

OVERVIEW OF STATE REPORTING OF THE 2020 ADULT CORE SET



Number of Adult Core Set Measures Reported by States, FFY 2020



States reported a median of

Adult Core Set

measures for FFY 2020

Sources: Mathematica analysis of MAC Proreports for the FFY 2020 reporting cycle as of June 18, 2021 and National Core Indicators (NCI) data submitted by states to the NCI National Team for the July 1, 2019 to June 30, 2020 data collection period.


Notes: The term "states" includes the 50 states, the District of Columbia, and Puerto Rico.

The following states did not report Adult Core Set measures for FFY 2020: Alaska and Montana.

The 2020 Adult Core Set includes 33 measures. This chart includes all Adult Core Set measures that states reported for the FFY 2020 reporting cycle. The state median includes the total number of measures reported by each state. Unless otherwise specified, states used Adult Core Set specifications to calculate the measures. Some states calculated Adult Core Set measures using "other specifications." Measures were denoted as using "other specifications" when the state deviated substantially from the Adult Core Set specifications, such as using alternate data sources, different populations, or other methodologies.



Number of States Reporting the Adult Core Set Measures, FFY 2020



23 states reported more Adult Core Set measures for FFY 2020 than for FFY 2019

Sources: Mathematica analysis of MAC Pro reports for the FFY 2020 reporting cycle as of June 18, 2021 and National Core Indicators (NCI) data submitted by states to the NCI National Team for the July 1, 2019 to June 30, 2020 data collection period.


Notes: The term "states" includes the 50 states, the District of Columbia, and Puerto Rico.

The 2020 Adult Core Set includes 33 measures. This chart includes all Adult Core Set measures that states reported for the FFY 2020 reporting cycle. Unless otherwise specified, states used Adult Core Set specifications to calculate the measures. Some states calculated Adult Core Set measures using "other specifications." Measures were denoted as using "other specifications" when the state deviated substantially from the Adult Core Set specifications, such as using alternate data sources, different populations, or other methodologies.

AOD = Alcohol and Other Drug; CAHPS = Consumer Assessment of Healthcare Providers and Systems; COPD = Chronic Obstructive Pulmonary Disease; ED = Emergency Department; HIV = Human Immunodeficiency Virus.



Number of States Reporting the Adult Core Set Measures, FFY 2018–FFY 2020




State reporting increased for

of the 29 measures included in the Adult Core Set for all three years



Number of States Reporting the Adult Core Set Measures, FFY 2018–FFY 2020 (continued)



Sources: Mathematica analysis of FFY 2018–FFY 2020 MACPro reports and National Core Indicators data submitted by states to the NCI National Team for the July 1, 2019 to June 30, 2020 data collection period.

Notes: The term "states" includes the 50 states, the District of Columbia, and Puerto Rico.


The 2020 Adult Core Set includes 33 measures. This chart includes all Adult Core Set measures that states reported for the FFY 2020 reporting cycle. Unless otherwise specified, states used Adult Core Set specifications to calculate the measures. Some states calculated Adult Core Set measures using "other specifications." Measures were denoted as using "other specifications" when the state deviated substantially from the Adult Core Set specifications, such as using alternate data sources, different populations, or other methodologies.

Data from previous years may be updated based on new information received after publication of the 2020 Chart Pack.

NA = not applicable; measure not included in the Adult Core Set for the reporting period; AOD = Alcohol and Other Drug; CAHPS = Consumer Assessment of Healthcare Providers and Systems; COPD = Chronic Obstructive Pulmonary Disease; ED = Emergency Department; HIV = Human Immunodeficiency Virus.



Geographic Variation in the Number of Adult Core Set Measures Reported by States, FFY 2020




states reported at least 27 of the 33 Adult Core Set measures for FFY 2020

Sources: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021 and National Core Indicators (NCI) data submitted by states to the NCI National Team for the July 1, 2019 to June 30, 2020 data collection period.

Notes: The term "states" includes the 50 states, the District of Columbia, and Puerto Rico. The 2020 Adult Core Set includes 33 measures. For FFY 2020, Adult Core Set reporting includes Idaho, Maine, North Dakota, and Puerto Rico for the first time.




Populations Included in Frequently Reported Adult Core Set Measures for FFY 2020, By Domain






Populations Included in Frequently Reported Adult Core Set Measures for FFY 2020, By Domain



Sources: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021 and National Core Indicators (NCI) data submitted by states to the NCI National Team for the July 1, 2019 to June 30, 2020 data collection period.

Notes: This chart includes measures that were reported by at least 25 states for FFY 2020 that met CMS standards for quality. "Dual eligibles" refers to beneficiaries dually enrolled in both Medicare and Medicaid. This chart excludes the Consumer Assessment of Healthcare Providers and Systems (CAHPS) measure.






All medians are reported as percentages except for measures PQI 01, PQI 05, PQI 08, and PQI 15, which are reported as rates per 100,000 beneficiary months.

Chart is continued on the next slide.






All medians are reported as percentages except for measures PQI 01, PQI 05, PQI 08, and PQI 15, which are reported as rates per 100,000 beneficiary months.

*Low er rates are better for this measure.

Chart is continued on the next slide.






All medians are reported as percentages except for measures PQI 01, PQI 05, PQI 08, and PQI 15, which are reported as rates per 100,000 beneficiary months.

*Low er rates are better for this measure.

Chart is continued on the next slide.






All medians are reported as percentages except for measures PQI 01, PQI 05, PQI 08, and PQI 15, which are reported as rates per 100,000 beneficiary months.

Chart is continued on the next slide.





Sources: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021 and National Core Indicators (NCI) data submitted by states to the NCI National Team for the July 1, 2019 to June 30, 2020 data collection period.

Notes: This chart includes measures that were reported by at least 25 states for FFY 2020 that met CMS standards for data quality. All medians are reported as percentages except for measures PQI 01, PQI 05, PQI 08, and PQI 15, which are reported as rates per 100,000 beneficiary months. This chart excludes the Plan All-Cause Readmissions measure, which uses a different summary statistic than those in this chart.

*Low er rates are better for this measure.



Primary Care Access and Preventive Care

Medicaid provides access to wellness visits and other preventive health care services, including immunizations, screenings, and counseling to support healthy living. Access to regular primary care and services can prevent infectious and chronic disease and other health conditions, help people live longer, healthier lives, and improve the health of the population.

Five Adult Core Set measures of primary care access and preventive care were available for analysis for FFY 2020. These measures are among the most frequently reported measures in the Adult Core Set.


- Breast Cancer Screening
- Cervical Cancer Screening
- Chlamydia Screening in Women Ages 21 to 24
- Adult Body Mass Index Assessment
- Flu Vaccinations for Adults Ages 18 to 64



Breast Cancer Screening

Breast cancer causes approximately 42,000 deaths in the United States each year. The U.S. Preventive Services Task Force recommends that women between the ages of 50 and 74 undergo mammography screening once every two years. Early detection via mammography screening and subsequent treatment can reduce breast cancer mortality for women in this age range.

Percentage of Women* Ages 50 to 74 who had a Mammogram to Screen for Breast Cancer (BCS-AD), FFY 2020 (n = 47 states)



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

Notes: This measure shows the percentage of women ages 50 to 74 w ho received a mammogram to screen for breast cancer during the measurement year or the two years prior to the measurement year.

*Data displayed in this chart include w omen ages 50 to 64 for 32 states and ages 50 to 74 for 15 states.

A median of


55

percent
of women received a
mammogram to screen
for breast cancer (47
states)



Breast Cancer Screening (continued)

Geographic Variation in the Percentage of Women* who had a Mammogram to Screen for Breast Cancer (BCS-AD), FFY 2020 (n = 47 states)



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.


*Data displayed in this chart include w omen ages 50 to 64 for 32 states and ages 50 to 74 for 15 states.



Cervical Cancer Screening

Approximately 14,500 new cases of cervical cancer and 4,300 deaths due to cervical cancer occur in the United States each year. The U.S. Preventive Services Task Force recommends that women ages 21 to 65 receive regular screening for cervical cancer through either a cervical cytology (Pap smear) test or, for women ages 30 to 65, a combination of cervical cytology and human papillomavirus (HPV) testing. When precancerous lesions or early stage cancer are detected through screening, cervical cancer can usually be prevented or treated effectively.

Percentage of Women Ages 21 to 64 who were Screened for Cervical Cancer (CCS-AD), FFY 2020 (n = 47 states)



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

This measure shows the percentage of women ages 21 to 64 w ho were screened for cervical cancer using one of the following criteria: (1) women ages 21 to 64 w ho had cervical cytology performed within the last 3 years; (2) women ages 30 to 64 w ho had cervical high-risk human papillomavirus (hrHPV) testing performed within the last 5 years; or (3) women ages 30 to 64 w ho had cervical cytology/high-risk human papillomavirus (hrHPV) co-testing within the last 5 years.

A median of


percent of women ages 21 to 64 were screened for cervical cancer (47 states)



Note:

Cervical Cancer Screening (continued)

Geographic Variation in the Percentage of Women Ages 21 to 64 who were Screened for Cervical Cancer (CCS-AD), FFY 2020 (n = 47 states)






Chlamydia Screening in Women Ages 21 to 24

Chlamydia is the most commonly reported sexually transmitted infection and easy to cure when it is detected. However, most people have no symptoms and are not aware they are infected. Left untreated, chlamydia can affect a woman's ability to have children. Recommended well care for young adult women who are sexually active includes annual screening for chlamydia. The Adult Core Set reports chlamydia screening rates for women ages 21 to 24.

Percentage of Sexually Active Women Ages 21 to 24 who were Screened for Chlamydia (CHL-AD), FFY 2020 (n = 48 states)



A median of

percent of sexually active women ages 21 to 24 were screened for chlamydia (48 states)


Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

Note: This measure shows the percentage of women ages 21 to 24 w ho were identified as sexually active and w ho had at least one test for chlamydia during the measurement year.



Chlamydia Screening in Women Ages 21 to 24 (continued)

Geographic Variation in the Percentage of Sexually Active Women Ages 21 to 24 who were Screened for Chlamydia (CHL-AD), FFY 2020 (n = 48 states)






Adult Body Mass Index Assessment

Monitoring of body mass index (BMI) helps providers identify adults who are overweight or obese and at increased risk for related health complications. The Adult BMI Assessment measure shows the percentage of beneficiaries with an outpatient visit whose BMI value was documented in the medical record.

Percentage of Adults* who had an Outpatient Visit and whose Body Mass Index Value was Documented in the Medical Record (ABA-AD), FFY 2020 (n = 39 states)



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

Note: This measure shows the percentage of adults ages 18 to 74 w ho had an outpatient visit and w hose body mass index (BMI) w as documented during the measurement year or the year prior to the measurement year.

*Data displayed in this chart include adults ages 18 to 64 for 23 states and ages 18 to 74 for 16 states.


A median of

percen of adults with an outpatient visit had their BMI value documented in the medical record (39 states)



Adult Body Mass Index Assessment (continued)

Geographic Variation in the Percentage of Adults* who had an Outpatient Visit with a Body Mass Index Value Documented in the Medical Record (ABA-AD), FFY 2020 (n = 39 states)



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

*Data displayed in this chart include adults ages 18 to 64 for 23 states and ages 18 to 74 for 16 states.




Flu Vaccinations for Adults Ages 18 to 64

Influenza (flu) is a highly contagious respiratory disease that can result in serious illness, hospitalization, and even death. Flu vaccination can prevent infections and reduce medical visits, hospitalizations, and deaths. In particular, flu vaccination is an important preventive tool for people with chronic health conditions who are at high risk for flu complications. The Centers for Disease Control and Prevention (CDC) recommends an annual flu vaccine for everyone six months and older. This measure assesses the percentage of adults ages 18 to 64 who reported receiving a flu vaccination. Performance on this measure is being publicly reported for the first time for FFY 2020.

Percentage of Adults Ages 18 to 64 who Received a Flu Vaccination (FVA-AD), FFY 2020

(n = 28 states)



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

Notes This measure shows the percentage of adults ages 18 to 64 w ho reported that they received either a flu shot or flu spray in the nose between July 1 of the measurement year and the date when the CAHPS 5.0H Adult Survey was completed for the measurement year. Rates are the percentage of beneficiaries answering "Yes" among the beneficiaries who answered "Yes" or "No" to the survey question.

A median of


percent of adults ages 18 to 64 received an influenza vaccination (28 states)



Flu Vaccinations for Adults Ages 18 to 64 (continued)

Geographic Variation in the Percentage of Adults Ages 18 to 64 who Received a Flu Vaccination (FVA-AD), FFY 2020







Maternal and Perinatal Health

As the largest payer for maternity care in the United States, Medicaid has an important role to play in improving maternal and perinatal health outcomes. Despite improvements in access to coverage and care, the rate of births reported as preterm or low birth weight among women in Medicaid is higher than the rate for those who are privately insured. The health of a child is affected by a mother's health and the care she receives during pregnancy. When women access the health care system for maternity care, an opportunity is presented to promote services and behaviors to optimize their health and the health of their children.

More information about CMS's efforts to improve maternal and infant health care quality is available at https://www.medicaid.gov/medicaid/quality-of-care/improvement-initiatives/maternal-infant-health-care-quality/index.html.

Three Adult Core Set measures of maternal and perinatal health were available for analysis for FFY 2020.

- Prenatal and Postpartum Care: Postpartum Care
- Contraceptive Care: Postpartum Women Ages 21 to 44
- Contraceptive Care: All Women Ages 21 to 44






Prenatal and Postpartum Care: Postpartum Care

Postpartum visits provide an opportunity to assess women's physical recovery from pregnancy and childbirth, and to address chronic health conditions (such as diabetes and hypertension), mental health status (including postpartum depression), and family planning (including contraception and inter-conception counseling). The postpartum care measure assesses how often women delivering a live birth received timely postpartum care (between 7 and 84 days after delivery).

Percentage of Women Delivering a Live Birth who had a Postpartum Care Visit on or Between 7 and 84 Days after Delivery (PPC-AD), FFY 2020 (n = 39 states)



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

This measure shows the percentage of deliveries of live births on or betw een October 8 of the year prior to the measurement year and October 7 of the measurement year that had a postpartum visit on or betw een 7 and 84 days after delivery. Specifications for this measure changed substantially for FFY 2020 and rates are not comparable with rates for previous years. This chart excludes Minnesota and Oregon, which reported the measure but did not use Core Set specifications


A median of

percent of women delivering a live birth had a postpartum care visit on or between 7 and 84 days after delivery (39 states)



Prenatal and Postpartum Care: Postpartum Care (continued)

Geographic Variation in the Percentage of Women Delivering a Live Birth who had a Postpartum Care Visit on or Between 7 and 84 Days after Delivery (PPC-AD), FFY 2020 (n = 39 states)








Contraceptive Care: Postpartum Women Ages 21 to 44

Access to effective contraceptive care during the postpartum period can improve birth spacing and timing and improve the health outcomes of women and children. This measure assesses access to contraceptive care, including the percentage of postpartum women ages 21 to 44 who were provided a most or moderately effective method of contraception as well as the percentage who were provided a long-acting reversible method of contraception (LARC) within 3 and 60 days of delivery.

Percentage of Postpartum Women Ages 21 to 44 who had a Live Birth and who were Provided a Most Effective or Moderately Effective Method of Contraception and the Percentage who were Provided a Long-Acting Reversible Method of Contraception (LARC) within 3 and 60 Days of Delivery (CCP-AD), FFY 2020



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

This measure shows the percentage of postpartum women ages 21 to 44 who had a live birth and who were provided: (1) a most effective or moderately effective method of contraception within 3 and 60 days of delivery; (2) a long-acting reversible method of contraception (LARC) within 3 and 60 days of delivery. Data were suppressed for the LARC 3-days postpartum rate for Wyoming due to small cell sizes.

Among postpartum women ages 21 to 44 who had a live birth, a median of

percent received a most or moderately effective method of contraception within 60 days of delivery (34 states)




Notes:

Contraceptive Care: Postpartum Women Ages 21 to 44: Most or Moderately Effective Method of Contraception 3-days Postpartum (continued)

Geographic Variation in the Percentage of Postpartum Women Ages 21 to 44 who had a Live Birth and who were Provided a Most Effective or Moderately Effective Method of Contraception within 3 Days of Delivery (CCP-AD), FFY 2020






Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.


Note: This chart excludes Kansas, which reported the measure but did not provide data for the most or moderately effective method of contraception 3-days postpartum rate.



Contraceptive Care: Postpartum Women Ages 21 to 44: Most or Moderately Effective Method of Contraception 60-days Postpartum (continued)

Geographic Variation in the Percentage of Postpartum Women Ages 21 to 44 who had a Live Birth and who were Provided a Most Effective or Moderately Effective Method of Contraception within 60 Days of Delivery (CCP-AD), FFY 2020 (n = 34 states)








Contraceptive Care: Postpartum Women Ages 21 to 44: LARC 3-days Postpartum (continued)

Geographic Variation in the Percentage of Postpartum Women Ages 21 to 44 who had a Live Birth and who were Provided a Long-Acting Reversible Method of Contraception (LARC) within 3 Days of Delivery (CCP-AD), FFY 2020

(n = 31 states)



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021


Note: This chart excludes Kansas and North Dakota, w hich reported the measure but did not provide data for the LARC 3-days postpartum rate. Data were suppressed for Wyoming due to small cell sizes.



Contraceptive Care: Postpartum Women Ages 21 to 44: LARC 60-days Postpartum (continued)

Geographic Variation in the Percentage of Postpartum Women Ages 21 to 44 who had a Live Birth and who were Provided a Long-Acting Reversible Method of Contraception (LARC) within 60 Days of Delivery (CCP-AD), FFY 2020

(n = 34 states)




Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.



Contraceptive Care: All Women Ages 21 to 44

Increasing access to effective forms of contraception is a strategy for reducing unintended pregnancy. This measure assesses the percentage of women ages 21 to 44 at risk of unintended pregnancy who were provided a most or moderately effective method of contraception as well as the percentage who were provided a long-acting reversible method of contraception (LARC). The goal of this measure is to provide an indicator to assess the provision of most or moderately effective contraceptive methods and see where there is room for improvement. Research suggests that about 44 percent of women ages 21 to 44 enrolled in Medicaid are not at risk of unintended pregnancy, which should be considered when assessing the potential for improvement on this measure.1 Performance on this measure is being publicly reported for the first time for FFY 2020.

Percentage of All Women Ages 21 to 44 at Risk of Unintended Pregnancy who were Provided a Most Effective or Moderately Effective Method of Contraception and the Percentage who were Provided a Long-Acting Reversible Method of Contraception (LARC) (CCW-AD), FFY 2020 (n = 31 states)



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

Note: This measure shows the percentage of women ages 21 to 44 at risk of unintended pregnancy who were provided: (1) a most or moderately effective method of contraception; (2) a long-acting reversible method of contraception (LARC).

1 More information is available at https://opa.hhs.gov/sites/default/files/2020-07/interpreting-rates-for-contraceptive-care

measures.pdf.


Among women ages 21 to 44 at risk of unintended pregnancy, a median of


percent received a most or moderately effective method of contraception (31 states)



Contraceptive Care: All Women Ages 21 to 44: Most or Moderately Effective Method of Contraception (continued)

Geographic Variation in the Percentage of All Women Ages 21 to 44 at Risk of Unintended Pregnancy who were Provided a Most Effective or Moderately Effective Method of Contraception (CCW-AD), FFY 2020 (n = 31 states)









Contraceptive Care: All Women Ages 21 to 44: LARC (continued)

Geographic Variation in the Percentage of All Women Ages 21 to 44 at Risk of Unintended Pregnancy who were Provided a Long-Acting Reversible Method of Contraception (LARC) (CCW-AD), FFY 2020 (n = 31 states)







Care of Acute and Chronic Conditions

The extent to which adults receive safe, timely, and effective care for acute and chronic conditions is a key indicator of the quality of care provided in Medicaid. Visits for routine screening and monitoring play an important role in managing the health care needs of people with acute and chronic conditions, potentially avoiding or slowing disease progression, and reducing costly avoidable hospital admissions and emergency department visits. The prevalence of chronic illnesses like diabetes is high among adults covered by Medicaid. Ensuring that adults receive timely, quality care may reduce the need for more costly care later and improve their chances of leading healthy, productive lives.

Eight Adult Core Set measures of the care of acute and chronic conditions were available for analysis for FFY 2020.

- Comprehensive Diabetes Care: Hemoglobin A1c (HbA1c) Poor Control (>9.0%)
- PQI 01: Diabetes Short-Term Complications Admission Rate
- PQI 05: Chronic Obstructive Pulmonary Disease (COPD) or Asthma in Older Adults Admission Rate
- PQI 08: Heart Failure Admission Rate
- PQI 15: Asthma in Younger Adults Admission Rate
- Plan All-Cause Readmissions
- Asthma Medication Ratio: Ages 19 to 64
- Controlling High Blood Pressure




https://firstfocus.org/wp-content/uploads/2014/05/Medicaid-Works.pdf

Comprehensive Diabetes Care: Hemoglobin A1c (HbA1c) Poor Control (>9.0%)

Among diabetic patients, a Hemoglobin A1c (HbA1c) level greater than 9.0% indicates poor control of diabetes. Poor control of diabetes is a risk factor for complications, including renal failure, blindness, and neurologic damage. This measure shows the percentage of adults with diabetes who had Hemoglobin A1c in poor control (>9.0%) during the measurement year.

Percentage of Adults* with Diabetes (Type 1 or Type 2) who had Hemoglobin A1c in Poor Control (>9.0%) (HPC-AD), FFY 2020 (n = 31 states) [Lower rates are better for this

measure]



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

otes: This measure shows the percentage of adults ages 18 to 75 w ith diabetes (type 1 or type 2) w ho had Hemoglobin A1c in poor control (>9.0%) during the measurement year. This chart excludes Arkansas, which calculated the measure but did not use Adult Core Set specifications.

A median of


percent of adults with diabetes had HbA1c in poor control (>9.0%) (31 states)



^{*}Data displayed in this chart include adults ages 18 to 64 for 16 states and ages 18 to 75 for 15 states.

Comprehensive Diabetes Care: Hemoglobin A1c (HbA1c) Poor Control (>9.0%) (continued)

Geographic Variation in the Percentage of Adults* with Diabetes (Type 1 or Type 2) who had Hemoglobin A1c in Poor Control (>9.0%) (HPC-AD), FFY 2020 (n = 31 states) [Lower rates are better for this measure]



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

Note: This chart excludes Arkansas, which calculated the measure but did not use Adult Core Set specifications.




^{*}Data displayed in this chart include adults ages 18 to 64 for 16 states and ages 18 to 75 for 15 states.

PQI 01: Diabetes Short-Term Complications Admission Rate

In the absence of access to high quality outpatient diabetes care, diabetic ketoacidosis, hyperosmolarity, and comas are acute, life-threatening complications of diabetes that can result in inpatient hospital admissions. Inpatient hospital admissions for these complications can be an indicator that diabetes is not being properly prevented or managed. This measure assesses the frequency of inpatient hospital admissions to treat short-term complications of diabetes among adult Medicaid beneficiaries.

Number of Inpatient Hospital Admissions for Diabetes Short-Term Complications per 100,000 Beneficiary Months for Adults* (PQI01-AD), FFY 2020 (n = 36 states) [Lower rates are better for this measure]



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

Note: This measure shows the number of inpatient hospital admissions for diabetes short-term complications (ketoacidosis, hyperosmolarity, or coma) per 100,000 beneficiary months for adults age 18 and older.

Adults age 18 and older had a median of


inpatient hospital admissions for diabetes short-term complications per 100,000 beneficiary months (36 states)



^{*}Data displayed in this chart include adults ages 18 to 64 for 34 states and age 18 and older for 2 states.

PQI 01: Diabetes Short-Term Complications Admission Rate (continued)

Geographic Variation in the Number of Inpatient Hospital Admissions for Diabetes Short-Term Complications per 100,000 Beneficiary Months for Adults* (PQI01-AD), FFY 2020 (n = 36 states) [Lower rates are better for this measure]



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.


*Data displayed in this chart include adults ages 18 to 64 for 34 states and age 18 and older for 2 states.



PQI 05: Chronic Obstructive Pulmonary Disease (COPD) or Asthma in Older Adults Admission Rate

Chronic obstructive pulmonary disease (COPD) is one of the most common chronic diseases in the United States and is currently the third leading cause of death in the U.S. population. Hospital admissions for COPD and asthma can often be avoided through high-quality outpatient care. This measure assesses the frequency of hospital admissions to treat COPD or asthma among Medicaid beneficiaries age 40 and older.

Number of Inpatient Hospital Admissions for Chronic Obstructive Pulmonary Disease (COPD) or Asthma per 100,000 Beneficiary Months for Adults* Age 40 and Older (PQI05-AD), FFY 2020 (n = 31 states) [Lower rates are better for this measure]



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

Note: This measure shows the number of inpatient hospital admissions for chronic obstructive pulmonary disease (COPD) or asthma per 100,000 beneficiary months for adults age 40 and older.

*Data displayed in this chart include adults ages 40 to 64 for 30 states and age 40 and older for 1 state.

Adults age 40 and older had a median of


inpatient hospital admissions for COPD or asthma per 100,000 beneficiary months (31 states)



PQI 05: Chronic Obstructive Pulmonary Disease (COPD) or Asthma in Older Adults Admission Rate (continued)

Number of Inpatient Hospital Admissions for Chronic Obstructive Pulmonary Disease (COPD) or Asthma per 100,000 Beneficiary Months for Adults* Age 40 and Older(PQI05-AD), FFY 2020 (n = 31 states) [Lower rates are better for this

measure]



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.


*Data displayed in this chart include adults ages 40 to 64 for 30 states and age 40 and older for 1 state.



PQI 08: Heart Failure Admission Rate

An estimated 6.2 million people in the United States have congestive heart failure (CHF). The most common causes of CHF are coronary artery disease, high blood pressure, and diabetes, all of which can be treated, controlled, and monitored in outpatient settings. Inpatient hospital admissions for heart failure can be an indicator that these conditions are not being properly prevented or managed. This measure assesses the frequency of inpatient hospital admissions for heart failure among adult Medicaid beneficiaries.

Number of Inpatient Hospital Admissions for Heart Failure per 100,000 Beneficiary Months for Adults* Age 18 and Older (PQI08-AD), FFY 2020 (n = 31 states) [Lower rates are better for this measure]



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

Note: This measure shows the number of inpatient hospital admissions for heart failure per 100,000 beneficiary months for adults age 18 and older.

Adults age 18 and older had a median of


inpatient hospital admissions for heart failure per 100,000 beneficiary months (31 states)



^{*}Data displayed in this chart include adults ages 18 to 64 for 30 states and age 18 and older for 1 state.

PQI 08: Heart Failure Admission Rate (continued)

Geographic Variation in the Number of Inpatient Hospital Admissions for Heart Failure per 100,000 Beneficiary Months for Adults* Age 18 and Older (PQI08-AD), FFY 2020 (n = 31 states) [Lower rates are better for this measure]



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.


*Data displayed in this chart include adults ages 18 to 64 for 30 states and age 18 and older for 1 state.



PQI 15: Asthma in Younger Adults Admission Rate

Asthma is one of the most common reasons for hospital admissions and emergency room visits among younger adults. These events are generally considered preventable with proper oversight and treatment in outpatient settings. This measure assesses the frequency of hospital admissions to treat asthma among Medicaid beneficiaries ages 18 to 39.

Number of Inpatient Hospital Admissions for Asthma per 100,000 Beneficiary Months for Adults Ages 18 to 39 (PQI15-AD), FFY 2020 (n = 31 states) [Lower rates are better for this measure]



Adults ages 18 to 39 had a median of

inpatient
hospital admissions for
asthma per 100,000
beneficiary months
(31 states)


Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

Notes: This measure shows the number of inpatient hospital admissions for asthma per 100,000 beneficiary months for adults ages 18 to 39. Data were suppressed for North Dakota due to small cell sizes.



PQI 15: Asthma in Younger Adults Admission Rate (continued)

Geographic Variation in the Number of Inpatient Hospital Admissions for Asthma per 100,000 Beneficiary Months for Adults Ages 18 to 39 (PQI15-AD), FFY 2020 (n = 31 states) [Lower rates are better for this measure]



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.


Note: Data were suppressed for North Dakota due to small cell sizes.



Plan All-Cause Readmissions

Unplanned readmissions to the hospital within 30 days of discharge are associated with adverse patient outcomes (including higher mortality) and higher health care costs. Readmissions may be prevented with coordination of care and support for patient self-management after discharge. This measure shows the ratio of observed readmissions to expected readmissions (O/E Ratio). The observed readmission rate is the number of acute inpatient stays during the measurement year for adults ages 18 to 64 that were followed by an unplanned acute readmission for any diagnosis within 30 days. This measure uses risk adjustment to calculate expected readmissions based on the characteristics of index hospital stays, including presence of surgeries, discharge condition, comorbidity, age, and gender.

Ratio of Observed All-Cause Readmissions to Expected Readmissions (O/E Ratio) among Adults Ages 18 to 64 (PCR-AD), FFY 2020 (n = 37 states) [Lower rates are better for this measure]



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

The Observed/Expected (O/E) Ratio is calculated as the ratio of the observed to expected readmissions and is rounded to four decimal places. The O/E Ratio is interpreted as "lower-is-better." An O/E ratio < 1.0 means there were fewer readmissions than expected given the case mix. An O/E ratio = 1 means that the number of readmissions was the same as expected given the case mix. An O/E ratio > 1.0 means that there were more readmissions than expected given the case mix. Specifications for this measure changed substantially for FFY 2020 and rates are not comparable with rates for previous years. This chart excludes Maine, which calculated the measure but did not use Adult Core Set specifications.

Of the 37 states reporting the measure,


states had fewer readmissions than expected given the case mix



Notes:

Plan All-Cause Readmissions (continued)

Geographic Variation in the Ratio of Observed All-Cause Readmissions to Expected Readmissions among Adults Ages 18 to 64 (PCR-AD), FFY 2020 (n = 37 states) [Lower rates are better for this measure]



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.


Note: This chart excludes Maine, w hich calculated the measure but did not use Adult Core Set specifications.



Asthma Medication Ratio: Ages 19 to 64

Asthma affects approximately 20 million adults in the United States. Uncontrolled asthma among adults can result in ED visits, hospitalizations, lost work days, and reduced productivity. The National Heart Lung and Blood Institute recommends long-term asthma control medications for adults with persistent asthma. This measure assesses the percentage of adults with persistent asthma who were dispensed appropriate asthma controller medications.

Percentage of Adults Ages 19 to 64 with Persistent Asthma who had a Ratio of Controller Medications to Total Asthma Medications of 0.50 or Greater (AMR-AD), FFY 2020 (n = 42 states)



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

Notes: This measure shows the percentage of adults ages 19 to 64 w ho were identified as having persistent asthma and w ho had a ratio of controller medications to total asthma medications of 0.50 or greater during the measurement year. Three rates are reported: (1) ages 19 to 50; (2) ages 51 to 64; and (3) a total rate for ages 19 to 64.


A median of

percent of adults ages 19 to 64 with persistent asthma had a ratio of controller medications to total asthma medications of 0.50 or greater (42 states)



Asthma Medication Ratio: Ages 19 to 50 (continued)


Geographic Variation in the Percentage of Adults Ages 19 to 50 with Persistent Asthma who had a Ratio of Controller Medications to Total Asthma Medications of 0.50 or Greater (AMR-AD), FFY 2020 (n = 42 states)





Asthma Medication Ratio: Ages 51 to 64 (continued)


Geographic Variation in the Percentage of Adults Ages 51 to 64 with Persistent Asthma who had a Ratio of Controller Medications to Total Asthma Medications of 0.50 or Greater (AMR-AD), FFY 2020 (n = 42 states)





Asthma Medication Ratio: Ages 19 to 64 (continued)

Geographic Variation in the Percentage of Adults Ages 19 to 64 with Persistent Asthma who had a Ratio of Controller Medications to Total Asthma Medications of 0.50 or Greater (AMR-AD), FFY 2020 (n = 42 states)






Controlling High Blood Pressure

High blood pressure, or hypertension, increases the risk of heart disease and stroke, which are the leading causes of death in the United States. Controlling high blood pressure is an important step in preventing heart attacks, strokes, and kidney disease, and in reducing the risk of developing other serious conditions. This measure assesses the percentage of Medicaid beneficiaries who had a diagnosis of hypertension and whose blood pressure was adequately controlled.

Percentage of Adults* who had a Diagnosis of Hypertension and whose Blood Pressure was Adequately Controlled (CBP-AD), FFY 2020 (n = 33 states)



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

otes: This measure shows the percentage of adults ages 18 to 85 w ho had a diagnosis of hypertension and w hose blood pressure was adequately controlled (<140/90 mm Hg) during the measurement year. This chart excludes Arkansas, w hich calculated the measure but did not use Adult Core Set specifications.

A median of


percent of adults with hypertension had their blood pressure adequately controlled (33 states)



^{*}Data displayed in this chart include adults ages 18 to 64 for 16 states and ages 18 to 85 for 17 states.

Controlling High Blood Pressure (continued)

Geographic Variation in the Percentage of Adults* who had a Diagnosis of Hypertension and whose Blood Pressure was Adequately Controlled (CBP-AD), FFY 2020 (n = 33 states)



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

Note: This chart excludes Arkansas, which calculated the measure but did not use Adult Core Set specifications.



^{*}Data displayed in this chart include adults ages 18 to 64 for 16 states and ages 18 to 85 for 17 states.

Behavioral Health Care

As the single largest payer for mental health services in the United States, Medicaid plays an important role in providing behavioral health care and monitoring the effectiveness of that care. For the purpose of the Adult Core Set, the term "behavioral health care" refers to treatment of mental health conditions and substance use disorders. Improvement of benefit design and service delivery for behavioral health care in Medicaid is a high priority for CMS, in collaboration with other federal agencies, states, providers, and consumers.

Ten Adult Core Set measures of behavioral health care were available for analysis for FFY 2020.

- Use of Opioids at High Dosage in Persons Without Cancer
- Concurrent Use of Opioids and Benzodiazepines
- Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment
- Medical Assistance With Smoking and Tobacco Use Cessation
- Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence
- Follow-Up After Emergency Department Visit for Mental Illness
- Follow-Up After Hospitalization for Mental Illness: Age 18 and Older
- Antidepressant Medication Management
- Adherence to Antipsychotic Medications for Individuals with Schizophrenia
- Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications




¹ For more information about Medicaid coverage of behavioral health care, see: https://www.medicaid.gov/medicaid/benefits/bhs/index.html.

Use of Opioids at High Dosage in Persons Without Cancer

Inappropriate prescribing and overuse of opioids is linked to an increased risk of morbidity and mortality. The Centers for Disease Control and Prevention recommends that clinicians prescribe opioids at the lowest effective dosage, consider individual benefits and risks when increasing dosage, and avoid increasing dosage to greater than or equal to 90 morphine milligram equivalents per day.

Percentage of Adults* Without Cancer who Received Prescriptions for Opioids with an Average Daily Dosage Greater than or Equal to 90 Morphine Milligram Equivalents for a Period of 90 Days or More (OHD-AD), FFY 2020 (n = 28 states) [Lower rates are better for

this measure]



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

This measure shows the percentage of adults age 18 and older w ho received prescriptions for opioids with an average daily dosage greater than or equal to 90 morphine milligram equivalents over a period of 90 days or more during the measurement year. Beneficiaries with a cancer diagnosis, sickle cell disease diagnosis, or in hospice are excluded. This chart excludes New Jersey, New York, Ohio, Pennsylvania, and Texas, which calculated the measure but did not use Adult Core Set specifications.

A median of


percent
of adults received
prescriptions for
opioids with an
average daily
dosage greater
than or equal to 90
Morphine Milligram
Equivalents over a
period of 90
consecutive days
or more (28 states)



^{*}Data displayed in this chart include adults ages 18 to 64 for 26 states and age 18 and older for 2 states.


Use of Opioids at High Dosage in Persons Without Cancer (continued)

Geographic Variation in the Percentage of Adults* Without Cancer who Received Prescriptions for Opioids with an Average Daily Dosage Greater than or Equal to 90 Morphine Milligram Equivalents for a Period of 90 Days or More (OHD-AD), FFY 2020 (n = 28 states) [Lower rates are better for this measure]



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

Note: This chart excludes New Jersey, New York, Ohio, Pennsylvania, and Texas, which calculated the measure but did not use Adult Core Set specifications.






Concurrent Use of Opioids and Benzodiazepines

The concurrent use of opioids and benzodiazepines can increase the risk for overdose and death and result in other adverse events, such as difficulty breathing. The Centers for Disease Control and Prevention (CDC) recommends that prescribers should avoid concurrent prescriptions of opioids and benzodiazepines. This measure assesses the percentage of adults age 18 and older that were prescribed both opioids and benzodiazepines for 30 or more cumulative days during the measurement year. Performance on this measure is being publicly reported for the first time for FFY 2020.

Percentage of Adults* with Concurrent Use of Prescription Opioids and Benzodiazepines for 30 or More Cumulative Days (COB-AD), FFY 2020 (n = 27 states) [Lower rates are better for this measure]



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

Es: This measure shows the percentage of adults age 18 and older with concurrent use of prescription opioids and benzodiazepines for 30 or more cumulative days during the measurement year. Adults with a cancer diagnosis, sickle cell disease diagnosis, or in hospice are excluded. Data were suppressed for West Virginia due to small cell sizes.

*Data displayed in this chart include adults ages 18 to 64 for 26 states and age 18 and older for 1 state.

A median of


16

percent of adults with 2 or more prescriptions for opioids, had concurrent prescriptions for opioids and benzodiazepines for 30 or more cumulative days (27 states)



Concurrent Use of Opioids and Benzodiazepines (continued)

Geographic Variation in the Percentage of Adults* with Concurrent Use of Prescription Opioids and Benzodiazepines for 30 or More Cumulative Days (COB-AD), FFY 2020 (n = 27 states) [Lower rates are better for this measure]



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021. Note: Data were suppressed for West Virginia due to small cell sizes.




^{*}Data displayed in this chart include adults ages 18 to 64 for 26 states and age 18 and older for 1 state.

Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment

Treatment for alcohol or other drug (AOD) abuse or dependence can improve health, productivity, and social outcomes, and can save millions of dollars on health care and related costs. This measure shows how often beneficiaries with newly-diagnosed AOD dependence initiated timely treatment (within 14 days of diagnosis), and then continued that treatment (two or more additional services or medication treatment within 34 days of the initiation visit).

Percentage of Adults* Age 18 and Older with a New Episode of Alcohol or Other Drug Abuse or Dependence who: (1) Initiated Treatment within 14 Days of the Diagnosis, and (2) Initiated Treatment and were Engaged in Ongoing Treatment within 34 Days of the Initiation Visit (IET-AD), FFY 2020



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

This measure shows the percentage of adults age 18 and older with a new episode of alcohol or other drug (AOD) abuse or dependence w ho: (1) initiated treatment through an inpatient AOD admission, outpatient visit, intensive outpatient encounter, partial hospitalization, telehealth, or medication treatment within 14 days of the diagnosis (initiation rate); and (2) initiated treatment and w ho were engaged in ongoing AOD treatment within 34 days of the initiation visit (engagement rate).

*Data displayed in this chart include adults ages 18 to 64 for 30 states and age 18 and older for 10 states.

A median of

percent
of adults with alcohol
or other drug abuse or
dependence initiated
treatment within 14
days of diagnosis
(40 states)


percent were engaged in ongoing treatment within 34 days of the initiation visit (40 states)



Note:


Initiation of Alcohol Abuse or Dependence Treatment (continued)

Geographic Variation in the Percentage of Adults* with a New Episode of Alcohol Abuse or Dependence Who Initiated Treatment within 14 Days of the Diagnosis (IET-AD), FFY 2020 (n = 39 states)



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.


Note: This chart excludes Georgia, w hich reported the measure but did not provide data for the Initiation of Alcohol Abuse or Dependence Treatment rate.






Engagement of Alcohol Abuse or Dependence Treatment (continued)

Geographic Variation in the Percentage of Adults* with a New Episode of Alcohol Abuse or Dependence Who Initiated Treatment and were Engaged in Ongoing Treatment within 34 Days of the Initiation Visit (IET-AD), FFY 2020



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.


Note: This chart excludes Georgia, which reported the measure but did not provide data for the Engagement of Alcohol Abuse or Dependence Treatment rate.





Initiation of Opioid Abuse or Dependence Treatment (continued)

Geographic Variation in Percentage of Adults* with a New Episode of Opioid Abuse or Dependence Who Initiated Treatment within 14 Days of the Diagnosis (IET-AD), FFY 2020 (n = 39 states)



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

Note: This chart excludes Georgia, w hich reported the measure but did not provide data for the Initiation of Opioid Abuse or Dependence Treatment rate.


*Data displayed in this chart include adults ages 18 to 64 for 29 states and age 18 and older for 10 states.



Engagement of Opioid Abuse or Dependence Treatment (continued)

Geographic Variation in the Percentage of Adults* with a New Episode of Opioid Abuse or Dependence Who Initiated Treatment and were Engaged in Ongoing Treatment within 34 Days of the Initiation Visit (IET-AD), FFY 2020

(n = 39 states)



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.


Note: This chart excludes Georgia, w hich reported the measure but did not provide data for the Engagement of Opioid Abuse or Dependence Treatment rate.

*Data displayed in this chart include adults ages 18 to 64 for 29 states and age 18 and older for 10 states.



Initiation of Other Drug Abuse or Dependence Treatment (continued)

Geographic Variation in Percentage of Adults* with a New Episode of Other Drug Abuse or Dependence Who Initiated Treatment within 14 Days of the Diagnosis (IET-AD), FFY 2020 (n = 39 states)



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

Note: This chart excludes Georgia, w hich reported the measure but did not provide data for the Initiation of Other Drug Abuse or Dependence Treatment rate.


*Data displayed in this chart include adults ages 18 to 64 for 29 states and age 18 and older for 10 states.



Engagement of Other Drug Abuse or Dependence Treatment (continued)


Geographic Variation in the Percentage of Adults* with a New Episode of Other Drug Abuse or Dependence Who Initiated Treatment and were Engaged in Ongoing Treatment within 34 Days of the Initiation Visit (IET-AD), FFY 2020





Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021


Note: This chart excludes Georgia, which reported the measure but did not provide data for the Engagement of Other Drug Abuse or Dependence Treatment rate.





Initiation of Alcohol or Other Drug Abuse or Dependence Treatment: Total Rate (continued)

Geographic Variation in the Percentage of Adults* with a New Episode of Alcohol or Other Drug Abuse or Dependence Who Initiated Treatment within 14 Days of the Diagnosis (Total Rate) (IET-AD), FFY 2020 (n = 40 states)




Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

*Data displayed in this chart include adults ages 18 to 64 for 30 states and age 18 and older for 10 states.



Engagement of Alcohol or Other Drug Abuse or Dependence Treatment: Total Rate (continued)

Geographic Variation in the Percentage of Adults* with a New Episode of Alcohol or Other Drug Abuse or Dependence Who Initiated Treatment and were Engaged in Ongoing Treatment within 34 Days of the Initiation Visit (Total Rate) (IET-AD), FFY 2020 (n = 40 states)



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.


*Data displayed in this chart include adults ages 18 to 64 for 30 states and age 18 and older for 10 states.



Medical Assistance With Smoking and Tobacco Use Cessation

Smoking and tobacco use are the leading cause of preventable disease and death in the United States. The CDC estimates that cigarette smoking causes nearly half a million deaths in the U.S. each year. Medical assistance with smoking and tobacco use cessation may reduce the prevalence of smoking and tobacco use, and ultimately prevent disease and improve health and quality of life. This measure assesses receipt of medical assistance with smoking and tobacco use cessation among adults age 18 and older who are current smokers or tobacco users. Performance on this measure is being publicly reported for the first time for FFY 2020.

Percentage of Adults Age 18 and Older who were Current Smokers or Tobacco Users and who (1) Were Advised to Quit, (2) Discussed or were Recommended Cessation Medications, (3) Discussed or were Provided Other Cessation Methods or Strategies (MSC-AD), FFY 2020 (n = 28 states)



Source: Notes: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

This measure shows the percentage of adults age 18 and older who reported that they were current smokers or tobacco users and who were provided medical assistance with smoking and tobacco use cessation in the six months prior to the survey. Rates are the percentage of beneficiaries who responded 'Sometimes,' 'Usually,' or 'Always' among beneficiaries who reported smoking 'Every Day' or 'Some Days.' Rates represent a rolling two-year average for the measurement year and prior year. Rates are not reported if fewer than 100 beneficiaries responded to the survey question. Data were suppressed for Oklahoma due to small cell sizes.

*Data displayed in this chart include adults ages 18 to 64 for 17 states and age 18 and older for 11 states.

A median of

percent of adults who were current smokers or tobacco users received advice to quit,

percent discussed cessation medications, and


percent discussed other cessation strategies (28 states)



Revised 01/2022

Advising Smokers and Tobacco Users to Quit (continued)

Geographic Variation in the Percentage of Adults* Age 18 and Older who were Current Smokers or Tobacco Users and Were Advised to Quit (MSC-AD), FFY 2020 (n = 28 states)



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.


Note: Data were suppressed for Oklahoma due to small cell sizes.



^{*}Data displayed in this chart include adults ages 18 to 64 for 17 states and age 18 and older for 11 states.

Discussing Cessation Medications (continued)

Geographic Variation in Percentage of Adults* Age 18 and Older who were Current Smokers or Tobacco Users and Discussed or were Recommended Cessation Medications (MSC-AD), FFY 2020 (n = 28 states)



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.


Note: Data were suppressed for Oklahoma due to small cell sizes.



^{*}Data displayed in this chart include adults ages 18 to 64 for 17 states and age 18 and older for 11 states.

Discussing Cessation Strategies (continued)

Geographic Variation in the Percentage of Adults* Age 18 and Older who were Current Smokers or Tobacco Users and Discussed or were Provided Cessation Methods or Strategies (MSC-AD), FFY 2020 (n = 28 states)



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

Note: Data were suppressed for Oklahoma due to small cell sizes.




^{*}Data displayed in this chart include adults ages 18 to 64 for 17 states and age 18 and older for 11 states.

Follow-up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence

Timely follow-up care after an emergency department (ED) visit for alcohol or other drug (AOD) abuse or dependence may reduce repeat ED visits, prevent hospital admissions, and improve health outcomes. The period immediately after the ED visit is important for engaging individuals in substance use treatment and establishing continuity of care. This measure shows the percentage of beneficiaries who had a follow-up visit with any practitioner within 7 and 30 days of an ED visit for AOD abuse or dependence.

Percentage of Emergency Department (ED) Visits for Adults* Age 18 and Older who had a Principal Diagnosis of Alcohol and Other Drug (AOD) Abuse or Dependence with a Follow-Up Visit within 7 Days and 30 Days of the ED Visit (FUA-AD), FFY 2020 (n = 41 states)



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

es: This measure shows the percentage of emergency department (ED) visits for adults age 18 and older with a principal diagnosis of alcohol or other drug (AOD) abuse or dependence that had a follow -up visit for AOD abuse or dependence. Two rates are reported: (1) the percentage of ED visits for which the beneficiary had a follow -up visit for AOD abuse or dependence within 7 days of the ED visit; and (2) the percentage of ED visits for which the beneficiary had a follow -up visit for AOD abuse or dependence within 30 days of the ED visit.

*Data displayed in this chart include adults ages 18 to 64 for 30 states and age 18 and older for 11 states.

A median of


percent of ED visits for adults with a diagnosis of AOD abuse or dependence had a follow-up visit within 7 days and

percent had a follow-up visit within 30 days (41 states)



Follow-up after Emergency Department (ED) Visit for Alcohol and Other Drug Abuse or Dependence Within 7 Days of the ED Visit (continued)

Geographic Variation in the Percentage of Emergency Department (ED) Visits for Adults* Age 18 and Older who had a Principal Diagnosis of Alcohol and Other Drug (AOD) Abuse or Dependence with a Follow-Up Visit within 7 Days of the ED Visit (FUA-AD), FFY 2020 (n = 41 states)




Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.



^{*}Data displayed in this chart include adults ages 18 to 64 for 30 states and age 18 and older for 11 states.

Follow-up after Emergency Department (ED) Visit for Alcohol and Other Drug Abuse or Dependence Within 30 Days of the ED Visit (continued)

Geographic Variation in the Percentage of Emergency Department (ED) Visits for Adults* Age 18 and Older who had a Principal Diagnosis of Alcohol and Other Drug (AOD) Abuse or Dependence with a Follow-Up Visit within 30 Days of the ED Visit (FUA-AD), FFY 2020 (n = 41 states)



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.




 $^{^{\}star}$ Data displayed in this chart include adults ages 18 to 64 for 30 states and age 18 and older for 11 states.

Follow-up After Emergency Department Visit for Mental Illness

Timely follow-up care after an emergency department (ED) visit for mental illness or intentional self-harm may reduce repeat ED visits, prevent hospital admissions, and improve health outcomes. The period immediately after the ED visit is important for engaging individuals in mental health treatment and establishing continuity of care. This measure shows the percentage of beneficiaries who had a follow-up visit with any practitioner within 7 and 30 days of an ED visit for mental illness or intentional self-harm.

Percentage of Emergency Department (ED) Visits for Adults* Age 18 and Older who had a Principal Diagnosis of Mental Illness or Intentional Self-Harm with a Follow-Up Visit within 7 Days and 30 Days of the ED Visit (FUM-AD), FFY 2020 (n = 40 states)



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

This measure shows the percentage of emergency department (ED) visits for adults age 18 and older with a principal diagnosis of mental illness or intentional self-harmthat had a follow -up visit for mental illness. Two rates are reported: (1) the percentage of ED visits for which the beneficiary had a follow -up visit within 7 days of the ED visit; and (2) the percentage of ED visits for which the beneficiary had a follow -up visit within 30 days of the ED visit.

*Data displayed in this chart include adults ages 18 to 64 for 39 states, and age 18 and older for 1 state.

A median of

percent of ED visits for adults with mental illness or intentional self-harm diagnoses had a follow-up visit within 7 days and


percent had a follow-up visit within 30 days (40 states)



Note:

Follow-up after Emergency Department (ED) Visit for Mental Illness Within 7 Days of the ED Visit (continued)

Geographic Variation in the Percentage of Emergency Department (ED) Visits for Adults* Age 18 and Older who had a Principal Diagnosis of Mental Illness or Intentional Self-Harm with a Follow-Up Visit within 7 Days of the ED Visit (FUM-AD), FFY 2020 (n = 40 states)




Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

*Data displayed in this chart include adults ages 18 to 64 for 39 states, age 18 and older for 1 state.



Follow-up after Emergency Department (ED) Visit for Mental Illness Within 30 Days of the ED Visit (continued)

Geographic Variation in the Percentage of Emergency Department (ED) Visits for Adults* Age 18 and Older who had a Principal Diagnosis of Mental Illness or Intentional Self-Harm with a Follow-Up Visit within 30 Days of the ED Visit (FUM-AD), FFY 2020 (n = 40 states)



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.


*Data displayed in this chart include adults ages 18 to 64 for 39 states, age 18 and older for 1 state.



Follow-Up After Hospitalization for Mental Illness: Age 18 and Older

Follow-up care after hospitalization for mental illness or intentional self-harm helps improve health outcomes and prevent readmissions in the days following discharge from inpatient mental health treatment. Recommended post-discharge treatment includes a visit with an outpatient mental health practitioner within 30 days after discharge and ideally, within 7 days after discharge.

Percentage of Discharges for Adults Age 18 and Older Hospitalized for Treatment of Mental Illness or Intentional Self-Harm with a Follow-Up Visit with a Mental Health Practitioner within 7 and 30 Days After Discharge (FUH-AD), FFY 2020 (n = 48 states)



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

This measure shows the percentage of discharges for adults age 18 and older w how ere hospitalized for treatment of selected mental illness or intentional self-harm diagnoses w ho had a follow -up visit with a mental health practitioner. Two rates are reported: (1) the percentage of discharges for which the beneficiary received follow-up within 7 days after discharge; and (2) the percentage of discharges for which the beneficiary received follow-up within 30 days after discharge. This chart excludes Oregon, which reported the measure but did not use Core Set specifications.

A median of


percent of adults who were hospitalized for mental illness or intentional self-harm had a follow-up visit within 7 days after discharge and

percent had a follow-up visit within 30 days after discharge (48 states)



Follow-Up After Hospitalization for Mental Illness Within 7 Days After Discharge (continued)

Geographic Variation in the Percentage of Discharges for Adults Hospitalized for Treatment of Mental Illness or Intentional Self-Harm with a Follow-Up Visit with a Mental Health Practitioner within 7 Days After Discharge (FUH-AD), FFY 2020 (n = 48 states)




Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

Note: This chart excludes Oregon, which reported the measure but did not use Core Set specifications.



Follow-Up After Hospitalization for Mental Illness Within 30 Days After Discharge (continued)

Geographic Variation in the Percentage of Discharges for Adults Hospitalized for Treatment of Mental Illness or Intentional Self-Harm with a Follow-Up Visit with a Mental Health Practitioner within 30 Days After Discharge (FUH-AD), FFY 2020 (n = 48 states)



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.


Note: This chart excludes Oregon, which reported the measure but did not use Core Set specifications.



Antidepressant Medication Management

Effective management of antidepressant medication is an important standard of care for patients receiving treatment for depression. When individuals are first diagnosed with major depression, medication may be prescribed either alone or in combination with psychotherapy. An initial course of medication treatment is recommended for 12 weeks to choose an effective regimen and observe a clinical response (acute phase). Continued treatment for at least six months is recommended to prevent relapse and to maintain functioning (continuation phase).

Percentage of Adults* with a Diagnosis of Major Depression who were Treated with and Remained on an Antidepressant Medication (AMM-AD), FFY 2020



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

This measure shows the percentage of adults age 18 and older diagnosed with major depression who were treated with antidepressant medication and who remained on antidepressant medication treatment. Two rates are reported: (1) the percentage who remained on antidepressant medication treatment for the 12-week acute phase; and (2) the percentage who remained on antidepressant medication treatment for the 6-month continuation phase.

*Data displayed in this chart include adults ages 18 to 64 for 27 states and age 18 and older for 16 states.

A median of

percent of adults with a diagnosis of major depression who were treated with antidepressant medication remained on medication during the acute phase (43 states) and


percent remained on medication during the continuation phase (42 states)



Note:

Antidepressant Medication Management: Acute Phase Treatment (continued)

Geographic Variation in the Percentage of Adults* with a Diagnosis of Major Depression who were Treated with and Remained on an Antidepressant Medication for the Acute Phase (12 Weeks) (AMM-AD), FFY 2020 (n = 43 states)




Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

*Data displayed in this chart include adults ages 18 to 64 for 27 states and age 18 and older for 16 states.



Antidepressant Medication Management: Continuation Phase Treatment (continued)

Geographic Variation in the Percentage of Adults* with a Diagnosis of Major Depression who were Treated with and Remained on an Antidepressant Medication for the Continuation Phase (6 Months) (AMM-AD), FFY 2020 (n = 42 states)



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021. Note:

This chart excludes Idaho, which reported the measure but did not provide data for the Continuation Phase Treatment rate.




^{*}Data displayed in this chart include adults ages 18 to 64 for 26 states and age 18 and older for 16 states.

Adherence to Antipsychotic Medications for Individuals with Schizophrenia

Adherence to antipsychotics for the treatment of schizophrenia can reduce the risk of relapse or hospitalization. This measure shows the percentage of Medicaid beneficiaries with schizophrenia or schizoaffective disorder who remained on an antipsychotic medication for at least 80 percent of their treatment period.

Percentage of Adults Age 18 and Older with Schizophrenia or Schizoaffective Disorder who were Dispensed and Remained on an Antipsychotic Medication for at Least 80 Percent of their Treatment Period (SAA-AD), FFY 2020 (n = 43 states)



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

Note: This measure shows the percentage of adults age 18 and older during the measurement year with schizophrenia or schizoaffective disorder who were dispensed and remained on an antipsychotic medication for at least 80 percent of their treatment period.


A median of

percent of adults ages 19 to 64 with schizophrenia or schizoaffective disorder remained on an antipsychotic medication for at least 80 percent of their treatment period (43 states)



Adherence to Antipsychotic Medications for Individuals with Schizophrenia (continued)

Geographic Variation in the Percentage of Adults Age 18 and Older with Schizophrenia or Schizoaffective Disorder who were Dispensed and Remained on an Antipsychotic Medication for at Least 80 Percent of their Treatment Period (SAA-AD), FFY 2020 (n = 43 states)








Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications

Individuals with serious mental illness who use antipsychotics are at increased risk of developing diabetes. Lack of appropriate screening for diabetes among people with schizophrenia, schizoaffective disorder, or bipolar disorder who use antipsychotic medications can lead to adverse health outcomes if diabetes is not detected and treated. This measure assesses whether Medicaid beneficiaries with schizophrenia, schizoaffective disorder, or bipolar disorder who were dispensed an antipsychotic medication had a diabetes screening test.

Percentage of Adults Ages 18 to 64 with Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder who were Dispensed an Antipsychotic Medication and had a Diabetes Screening Test (SSD-AD), FFY 2020 (n = 44 states)



Source: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021.

This measure shows the percentage of adults ages 18 to 64 w ith schizophrenia, schizoaffective disorder, or bipolar disorder w ho were dispensed an antipsychotic medication and had a diabetes screening test during the measurement year.

A median of


percer of adults with schizophrenia, schizoaffective disorder, or bipolar disorder who were dispensed an antipsychotic had a diabetes screening test during the measurement year (44 states)



Note:

Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (continued)

Geographic Variation in the Percentage of Adults Ages 18 to 64 with Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder who were Dispensed an Antipsychotic Medication and had a Diabetes Screening Test (SSD-AD), FFY 2020



Centers for Medicare & Medicaid Services

Medicaid & CHIP

Health Care Quality Measures

Long-Term Services & Supports

Medicaid is the primary payer for long-term care services in the United States.¹ Medicaid covers long-term care services across a continuum of settings, including home- and community-based long-term services and supports (LTSS) and institutional facilities. More than 20 percent of total Medicaid spending is for long-term care spending.

CMS is working in partnership with states, providers, consumers, advocates, and other stakeholders to create a person-driven system in which Medicaid beneficiaries with disabilities and chronic conditions have choice, control, and access to a full array of services that promote their health, independence, and quality of life.

One Adult Core Set measure of long-term services and supports was available for analysis for FFY 2020.

National Core Indicators Survey




¹ https://www.medicaid.gov/medicaid/long-term-services-supports/index.html

National Core Indicators Survey

The National Core Indicators (NCI) provide information on beneficiaries' experience and self-reported outcomes of long-term services and supports for individuals with intellectual and developmental disabilities (I/DD) and their families. State-level performance on three measures of I/DD beneficiary experience are reported for FFY 2020. These measures are: (1) Life Decisions Scale; (2) Everyday Choices Scale; and (3) Always Has a Way to Get Places. Performance on these measures are being publicly reported for the first time for FFY 2020.

National Core Indicators Survey: Experiences and Self-Reported Outcomes of Long-Term Services and Supports of Adults Age 18 and Older with Intellectual and Developmental Disabilities (NCIDDS-AD), FFY 2020 (n = 25 states)



Source: Mathematica analysis of National Core Indicators (NCI) data submitted by states to the National Association of State Directors of Developmental Disabilities Services and the Human Services Research Institute (The NCI National Team) through the Online Data Entry System (ODESA) for the July 1, 2019 to June 30, 2020 data collection period.

Three measures of beneficiary experience from the NCI In-Person Survey (IPS) are reported for the Adult Core Set for FFY 2020: (1) Life Decisions Scale (percentage of adults who reported they chose or had some input in choosing their residence, work, day activity, staff, and roommates); (2) Every day Choices Scale (percentage of adults who reported they decided or had help deciding their daily schedule, how to spend money, and how to spend free time); and (3) Always Has a Way to Get Places measure (percentage of adults who reported they always have a way to get places when they need to go somewhere).

A median of

percent of adults reported they chose or had some input in life decisions,

percent reported they chose or had some input in choosing their daily activities, spending, and free time, and


percent reported they always had a means of transportation (25 states)



Notes:

National Core Indicators Survey: Life Decisions Scale (continued)

Percentage of Adults who Make Choices about Their Life Decisions, including Their Residence, Work, Day Activity, Staff, and Roommates (NCIDDS-AD), FFY 2020 (n = 25 states)




Source: Mathematica analysis of National Core Indicators (NCI) data submitted by states to the National Association of State Directors of Developmental Disabilities Services and the Human Services Research Institute (The NCI National Team) through the Online Data Entry System (ODESA) for the July 1, 2019 to June 30, 2020 data collection period.



National Core Indicators Survey: Everyday Choices Scale (continued)

Percentage of Adults who Reported They Decided or Had Help Deciding Their Daily Schedule, How to Spend Money, and How to Spend Free Time (NCIDDS-AD), FFY 2020 (n = 25 states)




Source: Mathematica analysis of National Core Indicators (NCI) data submitted by states to the National Association of State Directors of Developmental Disabilities Services and the Human Services Research Institute (The NCI National Team) through the Online Data Entry System (ODESA) for the July 1, 2019 to June 30, 2020 data collection period.



National Core Indicators Survey: Always Has A Way To Get Places (continued)

Percentage of Adults who Reported They Always Have a Way to Get Places When They Need to go Somewhere (NCIDDS-AD), FFY 2020 (n = 25 states)



Source: Mathematica analysis of National Core Indicators (NCI) data submitted by states to the National Association of State Directors of Developmental Disabilities Services and the Human Services Research Institute (The NCI National Team) through the Online Data Entry System (ODESA) for the July 1, 2019 to June 30, 2020 data collection period.



TRENDS IN STATE PERFORMANCE, FFY 2018-FFY 2020



Trends in State Performance, FFY 2018-FFY 2020: Introduction

CMS assessed trends in median state performance on 14 Adult Core Set measures publicly reported from FFY 2018 to FFY 2020.¹ To be trended, each measure must meet the following three criteria:

- The measure was publicly reported for each of the most recent three years. To be publicly reported, a measure must be reported by at least 25 states using Core Set specifications and must meet CMS standards for data quality.
- The measure was reported by a set of at least 20 states that used Core Set specifications in all three years.
- The measure specifications were comparable for all three years (no specification changes occurred during the three-year period that would make results incomparable across years).

Many factors may affect changes in the performance rates reported by states on the Adult Core Set measures. While shifts in access and quality may account for some of the changes in performance over time, other factors noted by states include changes in:


- The method and data used to calculate the measures
- The populations included in the measures (such as managed care versus fee-for-service)
- Other aspects of their Medicaid program that could affect reporting (such as transitions in data systems or delivery systems).

¹ A methods brief describing the criteria for trending performance on the Child and Adult Core Set measures from FFY 2018 to FFY 2020 is available https://www.medicaid.gov/medicaid/quality-of-care/downloads/methods-brief-ffy-2020.pdf. Statistical significance was determined using the Wilcoxon Signed-Rank test (p<.05).



Trends in State Performance, FFY 2018–FFY 2020: Primary Care Access and Preventive Care

Median state performance on the Breast Cancer Screening, Cervical Cancer Screening and Chlamydia Screening in Women Ages 21 to 24 measures did not change significantly from FFY 2018 to FFY 2020, among the states reporting the measures for all three years.



Source: Mathematica analysis of FFY 2018–FFY 2020 MACPro reports.


Notes: This chart includes the states that reported each measure using Adult Core Set specifications for all three years.

Data from previous years may be updated based on new information received after publication of the 2020 Chart Pack.



Trends in State Performance, FFY 2018–FFY 2020: Maternal and Perinatal Health

Median state performance on three rates in the Contraceptive Care: Postpartum Women Ages 21 to 44 measure increased significantly from FFY 2018 to FFY 2020 among the states reporting the measure for all three years, including the Most or Moderately Effective (MME) Method of Contraception 3-days Postpartum, MME Method of Contraception 60-days Postpartum, and Long-Acting Reversible Method of Contraception (LARC) 3-days Postpartum rates. Median state performance on the LARC 60-days Postpartum rate decreased significantly from FFY 2018 to FFY 2020 among the states reporting the measure for all three years.



FFY 2019

FFY 2020

Source: Mathematica analysis of FFY 2018-FFY 2020 MACPro reports.

Notes: This chart includes the states that reported the measure using Adult Core Set specifications for all three years.


Data from previous years may be updated based on new information received after publication of the 2020 Chart Pack.

FFY 2018



Trends in State Performance, FFY 2018–FFY 2020: Care of Acute and Chronic Conditions

Median state performance on the Comprehensive Diabetes Care: Hemoglobin A1c Poor Control and Asthma Medication Ratio: Ages 19 to 64 measures did not change significantly from FFY 2018 to FFY 2020 among the states reporting the measures for all three years.



Source: Mathematica analysis of FFY 2018–FFY 2020 MACPro reports.


Notes: This chart includes the states that reported each measure using Adult Core Set specifications for all three years. Data from previous years may be updated based on new information received after publication of the 2020 Chart Pack.

*Low er rates are better for this measure.



Trends in State Performance, FFY 2018–FFY 2020: Care of Acute and Chronic Conditions (continued)

The median rate on the PQI 05: COPD or Asthma in Older Adults Admission Rate measure decreased significantly from FFY 2018 to FFY 2020 among the states reporting the measure for all three years, representing higher performance because lower rates are better on this measure. The median rate on the PQI 01: Diabetes Short-Term Complications Admission Rate and PQI 08: Heart Failure Admission Rate measures increased significantly from FFY 2018 to FFY 2020 among the states reporting the measures for all three years, representing lower performance because lower rates are better on these measures. The median rate on the PQI 15: Asthma in Younger Adults Admission Rate measure did not change significantly during this period.



Source: Mathematica analysis of FFY 2018-FFY 2020 MACPro reports.


Notes: This chart includes the states that reported each measure using Adult Core Set specifications for all three years. Data from previous years may be updated based on new information received after publication of the 2020 Chart Pack.

*Low er rates are better for this measure.



Trends in State Performance, FFY 2018-FFY 2020: Behavioral Health Care

Median state performance on the Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment measure increased significantly from FFY 2018 to FFY 2020 among the states reporting the measure for all three years for five indicators, including the four Initiation of Treatment rates and the Engagement rate for Opioid Abuse or Dependence. Median state performance did not change significantly for three rates of Engagement in Treatment, including treatment for Alcohol Abuse or Dependence, Other Drug Abuse or Dependence, or Total Alcohol or Other Drug Abuse or Dependence.



Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment

Median FFY 2018 FFY 2019 FFY 2020

Source: Mathematica analysis of FFY 2018-FFY 2020 MACPro reports.


Notes: This chart includes the states that reported the measure using Adult Core Set specifications for all three years.

Data from previous years may be updated based on new information received after publication of the 2020 Chart Pack.



Trends in State Performance, FFY 2018–FFY 2020: Behavioral Health Care (continued)

Median state performance on the Antidepressant Medication Management, Adherence to Antipsychotics for Individuals with Schizophrenia, and Diabetes Screening for People With Schizophrenia or Bipolar Disorder Using Antipsychotic Medications measures increased significantly from FFY 2018 to FFY 2020.



Source: Mathematica analysis of FFY 2018–FFY 2020 MACPro reports.

Notes: This chart includes the states that reported each measure using Adult Core Set specifications for all three years.

Data from previous years may be updated based on new information received after publication of the 2020 Chart Pack.



REFERENCE TABLES AND ADDITIONAL RESOURCES



Overview of State Reporting of the Adult Core Set Measures, FFY 2020

	Number of Measures Reported	Breast Cancer Screening	Cervical Cancer Screening Chlamydia Screening in Women Ages	8	essme	nations tor	Screening for Depression and Follow-up Plan: Age 18 and Older	Prenatal and Postpartum Care:	Postpartum care PC-01: Elective Delivery	tra	es 21	Comprehensive Dishetes Care:	Alc Poor	PQI 01: Diabetes Short-Term Complications Admission Rate	PQI 05: COPD or Asthma in Older Adults Admission Rate	PQI 08: Heart Failure Admission Rate	PQI 15: Asthma in Younger Adults Admission Rate	Plan Al-Cause Readmissions	Asthma Medication Ratio: Ages 19 to 64	Controlling High Blood Pressure HIV Viral Load Suppression	Use of Opioids at High Dosage in Persons Without Cancer	Concurrent Use of Opioids and Benzodiazepines	Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment	Use of Pharmacotherapy for Opioid Use Disorder	Medical Assistance with Smoking and Tobacco Use Cessation	Follow-Up After Emergency Department Visit for Acohol and Other Drug Abuse or Dependence	Follow-Up After Emergency Department Visit for Mental Illness	Follow-Up After Hospitalization for Mental Illness: Age 18 and Older	Antidepressant Medication Management	Adherence to Antipsychotic Medications for Individuals with Schizophrenia	Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications	Diabetes Care for People With Serious Mental Illness: Hemoglobin Atc (HbAtc) Poor Control (>9.0%)	CAHPS Health Plan Survey 5.0H, Adult Version (Medicaid)	National Core Indicators Survey
Total	22 (Median)	47	47 4	48	39 2	8.	15	41	6	34	31	:	32	36	31	31	32	38	42	34 9	33	28	40	23	29	41	40	49	43	43	44	7	36	25
Alabama	27	Х	X	Х	X X	Χ	Х	Χ		Х	Х	Т		Χ	Х	Χ	Χ		Χ	X	Х	Χ	Х	Х	Х	Х	Х	Х	Χ	Х	Х		Χ	
Arizona	21	Χ	X .	Χ		-				Χ	Х			Χ	Χ	Χ	Χ	Χ	Χ		Х	Χ	Χ	Χ		Χ	Χ	Χ	Χ	Χ	Χ			
Arkansas	23		X	Χ		-			Χ	Χ	Х		Χ	Χ	Χ	Χ	Χ	Χ	Χ	Х	Х	Χ		Χ		Χ	Χ	Χ	Χ	Χ	Χ			Х
Calif ornia	25	Х	X	Χ	Х -	-	Χ	Х		Χ	Х		Χ	Χ			Χ	Χ	Χ	X X	X	Χ	Χ	Χ		Χ	Χ	Χ	Χ	Χ	Χ			
Colorado	7	Х				-				Х	Х								Χ										Χ		Х			Х
Connecticut	28	Х	X	Χ	X X	X		Х		Х	Х		Χ	Χ	Χ	Χ	Х	Χ	Χ	X	X	Χ	Χ	Χ	Χ	X	Χ	Χ	Х	Χ	X		Х	
Delaware	27	Х	Χ .	Χ	X	Χ		Χ		Х	Х		Χ	Χ				Χ	Χ	ХХ	Х	Χ	Χ	Χ	Χ	Χ	Χ	Χ	Χ	Χ	Χ	Х	Х	
Dist. of Col.	19	Х	X .	Χ	X	Χ		Χ		Х	Х		Χ					Χ	Χ	X					Χ		Χ	Χ	Χ	Χ	Χ		Х	
Florida	20	Χ	X	Χ	Χ -	-		Х		Χ			Χ					Χ	Χ	Х			Χ		Χ	Χ	Χ	Χ	Χ	Χ	Χ		Х	Х
Georgia	20	Х	X	X	Х -	-	Χ	Χ					Χ	Χ		Χ		Χ	Χ	X			Х			Х	Χ	Χ	Χ	Χ	Х			Х
Hawaii	22	Х	X	Χ	Χ -	-	Χ	Х					Χ	Χ	Χ	Χ	Χ	Χ	Χ	Х	Х		Χ			Χ	Χ	Χ	Χ	Χ	Χ			
Idaho	11	Х	X	Χ		-							Χ											Χ		Χ		Χ	Χ	Χ	Χ	Χ		
Illinois	20	Х	X	Χ	X	Χ		Χ		X	Х			Χ	Χ	Χ	Χ						Χ		Χ			Χ	Χ	Χ	Χ		Χ	X
Indiana	19	Х	X	Χ	Х -	-		Х					Χ	Χ	Χ	Χ	Χ	Χ		X			Х			Х	X	Χ	Χ		X			X
Iowa	30	Χ	X	Χ	X X	Χ	Χ		Χ	Х	Х		Χ	Χ	Χ	Χ	Χ	Χ	Χ	X	Х	Χ	Х	Χ	Χ	Χ	Χ	Χ	Χ	Χ	Χ	Χ	Χ	
Kansas	28	Х	Χ	Χ	X	Χ	Х	Χ		Х	Х		Х	Х			Χ	Χ	Χ	X	Х	Χ	Х		Х	Х	Х	Х	Χ	Χ	Х	Х	Χ	Х
Kentucky	16	Х	X	Χ	Х -	-		Х											Χ	X			Х			Х	X	Χ	Χ	Χ	Х		Χ	X
Louisiana	27	Х	X	Х	X X	Χ		Х	Х	Х	Х		Х	Х	Х	Χ	Χ	Χ	Χ	хх	Х	Χ	Х		Х			Χ	Χ	Χ	Х		Χ	
Maine	7	Х	X	Х														Χ	Χ									Х						Х
Mary land	21	Х	X	Χ	X Z	Χ		Χ					Χ	Χ	Х	Χ	Χ	Χ	Χ	X	X		Х	Χ	Х	Х		Χ					Χ	



Overview of State Reporting of the Adult Core Set Measures, FFY 2020 (continued)

	Number of Measures Reported	east Cancer S		Chlamydia Screening in Women Ages 21 to 24	Adult Body Mass Index Assessment	ations for Adults Ag	Screening for Depression and Follow-up Plan: Age 18 and Older	Post		Contraceptive Care: Postpartum Women Ages 21 to 44	Contraceptive Care: AI Women Ages 21 to 44	Comprehensive Diabetes Care: Hemoglobin Alc Poor Control (>9.0%)	I 01: Diabetes Short-Term mplications Admission Rate	PQI 05: COPD or Asthma in Older Adults Admission Rate	PQI 08: Heart Failure Admission Rate	PQI 15: Asthma in Younger Adults Admission Rate	Plan All-Cause Readmissions	ication Rati	Controlling High Blood Pressure HIV Viral Load Suppression	Use of Opioids at High Dosage in Persons Without Cancer	Concurrent Use of Opioids and Benzodiazepines	Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment	Use of Pharmacotherapy for Opioid Use Disorder	Medical Assistance with Smoking and Tobacco Use Cessation	Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence	Follow-Up After Emergency Department Visit for Mental Illness	Follow-Up After Hospitalization for Mental Illness: Age 18 and Older	Antidepressant Medication Management	Adherence to Antipsychotic Medications for Individuals with Schizophrenia	Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Ilsing Artipsychotic Medications	oetes C tal IIIn		National Core Indicators Survey
Massachusetts	29	Х	Χ	Χ	Х	Х	Χ	Х		Х	Х	Х	Х	Χ	Х	Х	Х	Χ	X	Х	Х	Х		Х	Х	Х	Х	Х	Х	Х		Х	Х
Michigan	22	X	Χ	Χ	Χ			Х		Χ	Χ		Χ	Χ	Χ	Χ	Χ	Χ		Х	Χ	X			X		Χ	Χ	Χ	Χ		Х	
Minnesota	25	Х	Χ	Χ		Χ		Х		Χ	Χ		Χ	Χ	Χ	Χ	Χ	Χ		Х	Χ	X	Χ	Χ	X	Χ	Χ	Χ	Χ	Χ		Х	
Mississippi	25	Х	Χ	Х	Χ			Х		Х	Х	Х		Х		Х	Χ	Χ	хх	Х	Χ	Х			Х	Х	Х	Χ	Х	Χ	Х	Х	
Missouri	25	Х	Χ	Χ		Χ		Х		Χ	Χ		Χ	Χ	Χ	Χ		Χ		Х	Χ	X	X	Χ	X	Χ	Χ	Χ	Χ	Χ		Х	Х
Nebraska	11	Х	Χ	Х	Χ															Х	Χ				Х	Х	Χ		Х				Х
Nev ada	19	Х						Х		Χ	Χ	Х	Χ	Χ	Χ	Χ			ХХ			X			X	Χ	Χ		Χ	Χ		Х	Х
New Hampshire	30	Х	Χ	Χ	Χ	Χ	Χ	Х		Χ	Χ	Х	Х	Χ	Χ	Χ	Χ	Χ	X	Х	Χ	X	Χ	Χ	X	Х	Χ	Χ	Χ	Χ	Х	Х	
New Jersey	23	X	Χ	Χ	Χ	Χ		Х		Χ	Χ	Х	Χ				Χ	Χ	X	Х				Х	X	Χ	Χ	Χ	Χ	Χ		Х	Х
New Mexico	21	Х	Χ	Χ	Χ	Χ	Χ	Х				Х	Х				Χ	Χ	X			X		Χ	X	Х	Х	Χ	Χ	Χ		Х	
New York	26	Х	Χ	Х		Χ	Χ			Х	Х		Х	Х	Χ	Х	Χ	Χ	X	Х	Х	Х	Х	Х	Х	Х	Х	Χ	Х	Х		Х	
North Carolina	21	Х	Χ	Χ				Х		Χ	Χ		Χ	Χ	Χ	Χ	Χ	Χ		Х	Χ	X				Χ	Χ	Χ	Χ	Χ			Х
North Dakota	26	Х	Χ	Χ	Χ	Χ				Χ		Х	Χ	Χ	Χ	Χ	Χ	Χ	X	Х	Χ	X	Χ	Χ	X	Χ	Χ	Χ	X	Χ		Х	
Ohio	19	Х	Χ	Χ	Χ			Х				Х					Χ	Χ	X	Х		X	Χ		X	Χ	Χ	Χ	Χ	Χ			Х
Oklahoma	27	X	Χ	Χ	Χ	Χ		Х		Χ	Χ		Χ	Χ	Χ	Χ	Χ	Χ		X	Χ	Х	Χ	Χ	Χ	Χ	Χ	Χ	Χ	Χ		Х	Х
Oregon	19		Χ	Χ		Χ	Χ	Х				Х	Χ	Χ	Χ	Χ	Χ		X			X		Χ	Χ	Χ	Χ					Х	Х
Pennsy Iv ania	31	X	Χ	Χ	Χ	Χ		Х	Χ	Χ	Χ	Х	Χ	Χ	Χ	Χ	Χ	Χ	X	Х	Χ	X	Χ	Χ	Χ	Χ	Χ	Χ	Χ	Χ	Χ	Х	Х
Puerto Rico	14	X	Χ	Χ	Χ			Х					Χ	Χ	Χ										Χ	Χ	Χ		Χ	Χ		Х	
Rhode Island	21	Х	Χ	Χ	Χ	Χ		Х				Х					Χ	Χ	ХХ			X		Χ	Χ	Χ	Χ	Χ	Χ	Χ		Х	Х
South Carolina	29	X	Χ	Χ	Χ	Χ	Χ	Х	Χ	Χ	Χ		Χ	Χ	Χ	Χ	Χ	Χ	X	Х	Χ	Х	Χ	Χ	Χ	Χ	Χ	Χ	Χ	Х		Х	



Overview of State Reporting of the Adult Core Set Measures, FFY 2020 (continued)

	Number of Measures Reported	Breast Cancer Screening	Cervical Cancer Screening	Chlamydia Screening in Women Ages	- ნ	ccinations for Adults	eening for Depression and Follow-u	פופו	rostpartum Sare	: Elective Delive	Contraceptive Care: Postpartum Women Ages 21 to 44	ntrac	Comprehensive Diabetes Care: Hemodlobin Alc Poor Control (>9.0%)	1 01: Diabetes Short-Term mplications Admission Rate	COPD or Asthma in	08: Heart Failur	PQI 15: Asthma in Younger Adults Admission Rate	Ė	Asthma Medication Ratio: Ages 19 to 64		of Opioids at High Do	Without Cancer Concurrent Use of Opioids and	iazepines	Initiation and Engagement of Acohol and Other Drug Abuse or Dependence Treatment	Use of Pharmacotherapy for Opioid Use Disorder	Medical Assistance with Smoking and Tobacco Use Cessation	/-Up After Em or Alcohol and	Follow-Up After Emergency Department Visit for Mental Illness	Up A	ressant Med	Adherence to Antipsychotic Medications for Individuals with Schizophrenia	Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Ae Using Antipsychotic Medications	Care for People With less: Hemoglobin Afd trol (>9.0%)		
South Dakota	9			Χ	Х	X			Χ		Χ										-)	(.		Χ					Χ					X	
Tennessee	30	Х	Χ	Χ	Х	X	Χ		Χ		Χ	Χ	Х	Χ	Х	Χ	Χ	Χ	Χ	X -	- >	(Χ	X	Χ	Χ	Χ	Χ	Χ	Χ	Χ	Χ		Х	Х
Texas	27	Х	Χ	Χ	Χ	X			Χ		Χ	Χ		Χ	Χ	Χ	Х	Χ	Χ	X >	()	ζ.	Χ	X		Χ	Χ	Χ	Χ	Χ	Χ	X		Х	
Utah	14	Х	Χ	Χ	Χ				Χ				Х					Χ	Χ	X -	- -								Χ	Χ	Χ	X			Х
Vermont	29	Х	Χ	Χ	Χ	X	Χ		Χ		Χ	Χ	Х	Χ	Χ	Χ	Χ	Χ	Χ	X -	- >	ζ.	Χ	X	Χ	Х	Χ	Χ	Χ	Χ	Χ	X		Х	
Virginia	19	Х	Χ	Χ	Х	X			Χ				Х						Χ	X -				Х		Х	Χ	Х	Х	Χ	Х	Х		Х	Х
Washington	27	Х	Χ	Χ	Х				Χ		Χ	Χ	Х	Χ	Х	Χ	Χ	Χ	Χ	X -	- >	(Χ	X	Χ	Χ	Χ	Χ	Χ	Χ	Χ	Χ		Х	
West Virginia	29	Х	Χ	Χ	Х	X			Χ	Χ	Χ	Χ	Х	Χ	Х	Χ	Χ	Χ	Χ	X -	-)	(Χ	X	Χ	Χ	Χ	Χ	Χ	Χ	Χ	X		Х	
Wisconsin	18	Х	Χ	Χ	Х				Χ				Х					Χ	Χ	X -	- -			X			Χ	Χ	Χ	Χ	Χ	Χ		Х	Х
Wyoming	19	Х	Χ	Χ	Х		Χ		Χ		Χ	Χ		Χ	Χ	Χ	Χ		Χ		- >	(Χ		Χ				Χ	Χ					Х

Sources: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021 and National Core Indicators (NCI) data submitted by states to the NCI National Team for the July 1, 2019 to June 30, 2020 data collection period.

Notes: The term "states" includes the 50 states, the District of Columbia, and Puerto Rico. The 2020 Adult Core Set includes 33 measures.

Two measures were retired from the 2020 Adult Core Set and two measures were added. Information about the updates to the 2020 Core Sets is available at https://www.medicaid.gov/federal-policy-guidance/downloads/cib111919.pdf. This table includes all Adult Core Set measures for the FFY 2020 reporting cycle, including measures that were reported by states using "other" specifications and measures for which the rates are not publicly reported due to CMS data suppression rules.

X = measure w as reported by the state; -- = measure w as not reported by the state.

The following states did not report Adult Core Set measures for FFY 2020: Alaska and Montana.



Performance Rates on Frequently Reported Adult Core Set Measures, FFY 2020

Measure Name	Rate Definition	Number of States Reporting Using Core Set Specifications	Mean	Median	Bottom Quartile	Top Quartile
Primary Care Access and Preventive Care						
Breast Cancer Screening	Percentage of Women who had a Mammogram to Screen for Breast Cancer: Ages 50 to 64	47	53.7	54.7	50.4	59.5
Cervical Cancer Screening	Percentage of Women Screened for Cervical Cancer: Ages 21 to 64	47	55.5	56.7	49.3	62.6
Chlamydia Screening in Women Ages 21 to 24	Percentage of Sexually Active Women Screened for Chlamydia: Ages 21 to 24	48	58.3	60.5	53.8	67.4
Adult Body Mass Index Assessment	Percentage who had an Outpatient Visit with a BMI Documented in the Medical Record: Ages 18 to 64	39	75.3	85.6	64.1	91.7
Flu Vaccinations for Adults Ages 18 to 64	Percentage who Received a Flu Vaccination: Ages 18 to 64	28	44.6	44.8	40.9	48.0
Maternal and Perinatal Health						
Prenatal and Postpartum Care: Postpartum Care	Percentage of Women Delivering a Live Birth who had a Postpartum Care Visit on or Between 7 and 84 Days after Delivery	39	67.8	72.3	65.7	77.0
Contraceptive Care: Postpartum Women Ages 21 to 44	Percentage of Postpartum Women Provided a Most Effective or Moderately Effective Method of Contraception Within 3 Days of Delivery: Ages 21 to 44	33	11.8	11.9	8.7	13.0
Contraceptive Care: Postpartum Women Ages 21 to 44	Percentage of Postpartum Women Provided a Most Effective or Moderately Effective Method of Contraception Within 60 Days of Delivery: Ages 21 to 44	34	40.4	41.6	35.2	46.0
Contraceptive Care: Postpartum Women Ages 21 to 44	Percentage of Postpartum Women Provided a Long-Acting Reversible Method of Contraception Within 3 Daysof Delivery: Ages 21 to 44	31	2.2	1.9	0.7	2.7
Contraceptive Care: Postpartum Women Ages 21 to 44	Percentage of Postpartum Women Provided a Long-Acting Reversible Method of Contraception Within 60 Daysof Delivery: Ages 21 to 44	34	12.6	12.6	9.5	15.6



Measure Name	Rate Definition	Number of States Reporting Using Core Set Specifications	Mean	Median	Bottom Quartile	Top Quartile
Maternal and Perinatal Health (continued)						
Contraceptive Care: All Women Ages 21 to 44	Percentage of Women at Riskfor Unintended Pregnancy Provided a Most Effective or Moderately Effective Method of Contraception: Ages 21 to 44	31	25.3	24.5	23.0	28.6
Contraceptive Care: All Women Ages 21 to 44	Percentage of Women at Risk for Unintended Pregnancy Provided a Long-Acting Reversible Method of Contraception: Ages 21 to 44	31	4.9	5.1	3.6	6.1
Care of Acute and Chronic Conditions						
Comprehensive Diabetes Care: Hemoglobin A1c Poor Control (>9.0%)	Percentage with Diabetes (Type 1 or Type 2) who had Hemoglobin A1c in Poor Control (>9.0%): Ages 18 to 64 [Lower rates are better]	31	44.0	39.0	47.8	34.9
PQI 01: Diabetes Short-Term Complications Admission Rate	Inpatient Hospital Admissions for Diabetes Short-Term Complications per 100,000 Beneficiary Months: Ages 18 to 64 [Lower rates are better]	36	22.2	20.1	26.7	15.4
PQI 05: Chronic Obstructive Pulmonary Disease (COPD) or Asthma in Older Adults Admission Rate	Inpatient Hospital Admissions for Chronic Obstructive Pulmonary Disease (COPD) or Asthma per 100,000 Beneficiary Months: Ages 40 to 64 [Lower rates are better]	31	69.4	56.4	85.2	41.3
PQI 08: Heart Failure Admission Rate	Inpatient Hospital Admissions for Heart Failure per 100,000 Beneficiary Months: Ages 18 to 64 [Lower rates are better]	31	31.6	24.4	34.5	19.4
PQI 15: Asthma in Younger Adults Admission Rate	Inpatient Hospital Admissions for Asthma per 100,000 Beneficiary Months: Ages 18 to 39 [Lower rates are better]	31	8.2	6.5	7.8	3.9
Plan All-Cause Readmissions	Ratio of Observed All-Cause Readmissions to Expected Readmissions: Ages 18 to 64 [Lower rates are better]	37	1.0259	1.0363	1.1449	0.9117



		Number of States Reporting Using				
Measure Name	Rate Definition	Core Set Specifications	Mean	Median	Bottom Quartile	Top Quartile
Care of Acute and Chronic Conditions (c	ontinued)					
Asthma Medication Ratio: Ages 19 to 64	Percentage with Persistent Asthma who had a Ratio of Controller Medications to Total Asthma Medications of 0.50 or Greater: Ages 19 to 50	42	52.6	53.7	49.6	55.3
Asthma Medication Ratio: Ages 19 to 64	Percentage with Persistent Asthma who had a Ratio of Controller Medications to Total Asthma Medications of 0.50 or Greater: Ages 51 to 64	42	54.3	54.6	50.7	57.3
Asthma Medication Ratio: Ages 19 to 64	Percentage with Persistent Asthma who had a Ratio of Controller Medications to Total Asthma Medications of 0.50 or Greater: Ages 19 to 64	42	53.4	53.7	50.9	56.4
Controlling High Blood Pressure	Percentage who had a Diagnosis of Hypertension and Whose Blood Pressure was Adequately Controlled: Ages 18 to 64	33	56.6	59.2	52.6	64.7
Behavioral Health Care						
Use of Opioids at High Dosage in Persons Without Cancer	Percentage of Adults Without Cancer who Received Prescriptions for Opioids with an Average Daily Dosage Greater than or Equal to 90 Morphine Milligram Equivalents (MME) for a Period of 90 Days or More [Lower rates are better]	28	7.3	6.5	9.6	3.9
Concurrent Use of Opioids and Benzodiazepines	Percentage with Concurrent Use of Prescription Opioids and Benzodiazepines: Ages 18 to 64 [Lower rates are better]	27	15.4	16.3	21.6	11.2
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment	Percentage with a New Episode of Alcohol Abuse or Dependence who Initiated Alcohol or Other Drug Treatment within 14 Days of the Diagnosis: Ages 18 to 64	39	40.4	40.8	36.8	43.7
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment	Percentage with a New Episode of Alcohol Abuse or Dependence who Initiated and Engaged in Alcohol or Other Drug Treatment within 34 Days of the Initiation Visit: Ages 18 to 64	39	11.9	12.5	8.0	15.2



		Number of States Reporting Using				
Measure Name	Rate Definition	Core Set Specifications	Mean	Median	Bottom Quartile	Top Quartile
Behavioral Health Care (continued)						
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment	Percentage with a New Episode of Opioid Abuse or Dependence who Initiated Alcohol or Other Drug Treatment within 14 Days of the Diagnosis: Ages 18 to 64	39	54.7	54.9	46.1	63.7
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment	Percentage with a New Episode of Opioid Abuse or Dependence who Initiated and Engaged in Alcohol or Other Drug Treatment within 34 Days of the Initiation Visit: Ages 18 to 64	39	30.1	30.1	17.0	39.5
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment	Percentage with a New Episode of Other Drug Abuse or Dependence who Initiated Alcohol or Other Drug Treatment within 14 Days of the Diagnosis: Ages 18 to 64	39	40.6	40.5	37.6	44.0
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment	Percentage with a New Episode of Other Drug Abuse or Dependence who Initiated and Engaged in Alcohol or Other Drug Treatment within 34 Days of the Initiation Visit: Ages 18 to 64	39	12.4	12.5	9.3	15.3
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment	Percentage with a New Episode of Alcohol or Other Drug Abuse or Dependence who Initiated Alcohol or Other Drug Treatment within 14 Days of the Diagnosis: Ages 18 to 64	40	43.4	42.7	39.3	48.2
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment	Percentage with a New Episode of Alcohol or Other Drug Abuse or Dependence who Initiated and Engaged in Alcohol or Other Drug Treatment within 34 Days of the Initiation Visit: Ages 18 to 64	40	16.5	16.0	11.7	19.5
Medical Assistance With Smoking and Tobacco Use Cessation	Percentage of Current Smokers and Tobacco Users Advised to Quit: Ages 18 to 64 Years	28	76.3	76.7	73.6	79.9
Medical Assistance With Smoking and Tobacco Use Cessation	Percentage of Current Smokers and Tobacco Users Discussed or Recommended Cessation Medications: Ages 18 to 64 Years	28	53.5	53.7	50.6	57.4
Medical Assistance With Smoking and Tobacco Use Cessation	Percentage of Current Smokers and Tobacco Users Discussed or Provided Other Cessation Strategies: Ages 18 to 64 Years	28	48.3	48.0	45.9	51.9



Measure Name	Rate Definition	Number of States Reporting Using Core Set Specifications	Mean	Median	Bottom Quartile	Top Quartile
Behavioral Health Care (continued)						
Follow-up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence	Percentage of Emergency Department (ED) Visits for Alcohol and Other Drug Abuse or Dependence with a Follow-Up Visit Within 7 Days of the ED Visit: Ages 18 to 64	41	15.7	15.2	7.8	20.3
Follow-up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence	Percentage of Emergency Department (ED) Visitsfor Alcohol and Other Drug Abuse or Dependence with a Follow-Up Visit Within 30 Daysof the ED Visit: Ages 18 to 64	41	22.7	22.5	11.5	30.1
Follow-up After Emergency Department Visit for Mental Illness	Percentage of Emergency Department (ED) Visitsfor Mental Illnessor Intentional Self-Harm with a Follow-Up Visit Within 7 Days of the ED Visit: Ages 18 to 64	40	40.9	39.6	30.5	49.7
Follow-up After Emergency Department Visit for Mental Illness	Percentage of Emergency Department (ED) Visitsfor Mental Illnessor Intentional Self-Harm with a Follow-Up Visit Within 30 Days of the ED Visit: Ages 18 to 64	40	54.3	52.1	46.6	63.1
Follow-Up After Hospitalization for Mental Illness: Age 18 and Older	Percentage of Hospitalizations for Mental Illness or Intentional Self-Harm with a Follow-Up Visit Within 7 Days after Discharge: Ages 18 to 64	48	34.3	33.1	24.1	44.4
Follow-Up After Hospitalization for Mental Illness: Age 18 and Older	Percentage of Hospitalizations for Mental Illness or Intentional Self-Harm with a Follow-Up Visit Within 30 Days after Discharge: Ages 18 to 64	48	52.4	54.7	40.5	65.6
Antidepressant Medication Management	Percentage Diagnosed with Major Depression who were Treated with and Remained on Antidepressant Medication for 12 Weeks: Ages 18 to 64	43	52.5	53.1	47.5	57.4
Antidepressant Medication Management	Percentage Diagnosed with Major Depression who were Treated with and Remained on Antidepressant Medication for 6 Months: Ages 18 to 64	42	35.9	37.3	29.9	41.1
Adherence to Antipsychotic Medicationsfor Individuals with Schizophrenia	Percentage with Schizophrenia or Schizoaffective Disorder who were Dispensed and Remained on Antipsychotic Medication for at Least 80 Percent of their Treatment Period: Age 18 and older	43	61.2	62.5	56.6	67.0



Measure Name	Rate Definition	Number of States Reporting Using Core Set Specifications	Mean	Median	Bottom Quartile	Top Quartile
Behavioral Health Care (continued)						
Diabetes Screening for People with Schizophrenia or Bipolar Disorder Using Antipsychotics	Percentage with Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder who were Dispensed an Antipsychotic Medication and had a Diabetes Screening Test: Ages 18 to 64	44	79.8	80.3	77.3	82.5
Long-Term Services & Supports						
National Core Indicators Survey	Percentage of Adults who Make Choices about Their Life Decisions, including Their Residence, Work, Day Activity, Staff, and Roommates	25	67.2	68.6	61.2	74.8
National Core Indicators Survey	Percentage of Adults who Reported They Decided or Had Help Deciding Their Daily Schedule, How to Spend Money, and How to Spend Free Time	25	91.8	92.9	89.6	93.9
National Core Indicators Survey	Percentage of Adults who Reported They Always Have a Way to Get Places when They Need to Go Somewhere	25	93.6	95.0	92.0	96.8

Sources: Mathematica analysis of MACPro reports for the FFY 2020 reporting cycle as of June 18, 2021 and National Core Indicators (NCI) data submitted by states to the NCI National Team for the July 1, 2019 to June 30, 2020 data collection period.

Notes: The term "states" includes the 50 states, the District of Columbia, and Puerto Rico.

This table includes measures that were reported by at least 25 states for FFY 2020 and that met CMS standards for data quality. This table includes data for states that indicated they used Adult Core Set specifications to report the measures and excludes states that indicated they used other specifications and states that did not report the measures for FFY 2020. Additionally, some states were excluded because data cannot be displayed per the CMS cell-size suppression policy, which prohibits the direct reporting of data for beneficiary and record counts of 1 to 10 and values from which users can derive values of 1 to 10. Means are calculated as the unw eighted average of all state rates. Measure-specific tables are available at https://www.medicaid.gov/medicaid/quality-of-care/performance-measurement/adult-and-child-health-care-quality-measures/adult-health-care-quality-measures/index.html. The CAHPS Health Plan Survey measure is excluded from this table because it uses a summary statistic different from those in this table.



Trends in Performance Rates on Frequently Reported Adult Core Set Measures, FFY 2018–FFY 2020

		Number of States Reporting Using Core Set			
Measure Name	Rate Definition	Specifications FFY 2018–FFY 2020	FFY 2018 Median	FFY 2019 Median	FFY 2020 Median
Primary Care Access and Preventive Care					
Breast Cancer Screening	Percentage of Women who had a Mammogram to Screen for Breast Cancer: Ages 50 to 64	41	54.6	53.7	53.8
Cervical Cancer Screening	Percentage of Women Screened for Cervical Cancer: Ages 21 to 64	40	56.1	55.4	57.4
Chlamydia Screening in Women Ages 21 to 24	Percentage of Sexually Active Women Screened for Chlamydia: Ages 21 to 24	38	60.8	60.7	61.7
Maternal and Perinatal Health					
Contraceptive Care: Postpartum Women Ages 21 to 44	Percentage of Postpartum Women Provided a Most Effective or Moderately Effective Method of Contraception Within 3 Days of Delivery: Ages 21 to 44	27	10.8	11.2	11.9
Contraceptive Care: Postpartum Women Ages 21 to 44	Percentage of Postpartum Women Provided a Most Effective or Moderately Effective Method of Contraception Within 60 Days of Delivery: Ages 21 to 44	27	39.4	39.9	42.7
Contraceptive Care: Postpartum Women Ages 21 to 44	Percentage of Postpartum Women Provided a Long- Acting Reversible Method of Contraception Within 3 Days of Delivery: Ages 21 to 44	26	0.8	1.6	2.0
Contraceptive Care: Postpartum Women Ages 21 to 44	Percentage of Postpartum Women Provided a Long- Acting Reversible Method of Contraception Within 60 Days of Delivery: Ages 21 to 44	27	12.9	12.6	12.7
Care of Acute and Chronic Conditions					
Comprehensive Diabetes Care: Hemoglobin A1c Poor Control (>9.0%)	Percentage with Diabetes (Type 1 or Type 2) who had Hemoglobin A1c in Poor Control (>9.0%): Ages 18 to 64 [Lower rates are better]	24	39.3	39.2	37.5
Asthma Medication Ratio: Ages 19 to 64	Percentage with Persistent Asthma who had a Ratio of Controller Medications to Total Asthma Medications of 0.50 or Greater: Ages 19 to 50	28	52.8	53.9	53.9
Asthma Medication Ratio: Ages 19 to 64	Percentage with Persistent Asthma who had a Ratio of Controller Medications to Total Asthma Medications of 0.50 or Greater: Ages 51 to 64	26	55.3	56.5	54.9



Measure Name	Rate Definition	Number of States Reporting Using Core Set Specifications FFY 2018-FFY 2020	FFY 2018 Median	FFY 2019 Median	FFY 2020 Median
Care of Acute and Chronic Conditions (continued)				
Asthma Medication Ratio: Ages 19 to 64	Percentage with Persistent Asthma who had a Ratio of Controller Medications to Total Asthma Medications of 0.50 or Greater: Ages 19 to 64	27	53.1	54.6	53.7
PQI 01: Diabetes Short-Term Complications Admission Rate	Inpatient Hospital Admissions for Diabetes Short-Term Complications per 100,000 Beneficiary Months: Ages 18 to 64 [Lower rates are better]	28	16.4	19.1	20.1
PQI 05: Chronic Obstructive Pulmonary Disease (COPD) or Asthma in Older Adults Admission Rate	Inpatient Hospital Admissions for Chronic Obstructive Pulmonary Disease (COPD) or Asthma per 100,000 Beneficiary Months: Ages 40 to 64 [Lower rates are better]	24	93.5	71.9	62.8
PQI 08: Heart Failure Admission Rate	Inpatient Hospital Admissions for Heart Failure per 100,000 Beneficiary Months: Ages 18 to 64 [Lower rates are better]	24	24.4	24.8	25.6
PQI 15: Asthma in Younger Adults Admission Rate	Inpatient Hospital Admissions for Asthma per 100,000 Beneficiary Months: Ages 18 to 39 [Lower rates are better]	24	6.5	6.1	6.6
Behavioral Health Care					
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment	Percentage with a New Episode of Alcohol Abuse or Dependence who Initiated Alcohol or Other Drug Treatment within 14 Days of the Diagnosis: Ages 18 to 64	31	38.9	40.0	41.0
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment	Percentage with a New Episode of Alcohol Abuse or Dependence who Initiated and Engaged in Alcohol or Other Drug Treatment within 34 Days of the Initiation Visit Ages 18 to 64	31	11.7	11.4	12.7
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment	Percentage with a New Episode of Opioid Abuse or Dependence who Initiated Alcohol or Other Drug Treatment within 14 Days of the Diagnosis: Ages 18 to 64	31	46.3	54.5	57.2
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment	Percentage with a New Episode of Opioid Abuse or Dependence who Initiated and Engaged in Alcohol or Other Drug Treatment within 34 Days of the Initiation Visit Ages 18 to 64	31	26.3	27.7	30.1



Measure Name	Rate Definition	Number of States Reporting Using Core Set Specifications FFY 2018–FFY 2020	FFY 2018 Median	FFY 2019 Median	FFY 2020 Median
Behavioral Health Care (continued)					
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment	Percentage with a New Episode of Other Drug Abuse or Dependence who Initiated Alcohol or Other Drug Treatment within 14 Days of the Diagnosis: Ages 18 to 64	31	38.0	40.1	40.5
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment	Percentage with a New Episode of Other Drug Abuse or Dependence who Initiated and Engaged in Alcohol or Other Drug Treatment within 34 Days of the Initiation Visit Ages 18 to 64	31	11.2	10.8	12.2
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment	Percentage with a New Episode of Alcohol or Other Drug Abuse or Dependence who Initiated Alcohol or Other Drug Treatment within 14 Days of the Diagnosis: Ages 18 to 64	33	40.0	42.0	43.9
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment	Percentage with a New Episode of Alcohol or Other Drug Abuse or Dependence who Initiated and Engaged in Alcohol or Other Drug Treatment within 34 Days of the Initiation Visit: Ages 18 to 64	33	14.9	16.6	17.0
Antidepressant Medication Management	Percentage Diagnosed with Major Depression who were Treated with and Remained on Antidepressant Medication for 12 Weeks: Ages 18 to 64	33	50.3	51.3	53.1
Antidepressant Medication Management	Percentage Diagnosed with Major Depression who were Treated with and Remained on Antidepressant Medication for 6 Months: Ages 18 to 64	33	34.8	34.4	37.5
Adherence to Antipsychotic Medications for Individuals with Schizophrenia	Percentage with Schizophrenia or Schizoaffective Disorder who were Dispensed and Remainedon Antipsychotic Medication for at Least 80 Percent of their Treatment Period: Age 18 and older	33	57.7	60.6	62.1
Diabetes Screening for People with Schizophrenia or Bipolar Disorder Using Antipsychotic Medications	Percentage with Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder who were Dispensed an Antipsychotic Medication and had a Diabetes Screening Test: Ages 18 to 64	32	80.1	80.0	80.3

Source: Mathematica analysis of FFY 2018–FFY 2020 MAC Pro reports.

Notes: The term "states" includes the 50 states, the District of Columbia, and Puerto Rico.

This table includes measures that each met the following criteria: (1) the measure was publicly reported for each of the most recent three years. To be publicly reported, a measure must be reported by at least 25 states using Core Set specifications and must meet CMS standards for data quality; (2) the measure was reported by a set of at least 20 states that used Core Set specifications in all three years; (3) the measure specifications were comparable for all three years. Data from previous years may be updated based on new information received after publication of the 2020 Chart Pack.

Measure-specific tables are available at https://www.medicaid.gov/medicaid/quality-of-care/performance-measurement/adult-and-child-health-care-quality-measures/index.html.



Acronyms

AOD Alcohol and Other Drug

BMI Body Mass Index

CAHPS Consumer Assessment of Healthcare Providers and Systems

CHF Congestive Heart Failure

CHIP Children's Health Insurance Program

CMS Centers for Medicare & Medicaid Services

COPD Chronic Obstructive Pulmonary Disease

ED Emergency Department

FFY Federal Fiscal Year

HbA1c Hemoglobin A1c

HIV Human Immunodeficiency Virus

HPV Human Papillomavirus

I/DD Intellectual and Developmental Disabilities

LARC Long-Acting Reversible Method of Contraception

MACPro Medicaid and CHIP Program System

MME Most or Moderately Effective



Acronyms (continued)

NCI National Core Indicators

O/E Observed-to-Expected

PC Perinatal Care

PQI Prevention Quality Indicator



Additional Resources

Additional resources related to the Adult Core Set are available at https://www.medicaid.gov/medicaid/quality-of-care/performance-measurement/adult-core-set/index.html.

These resources include:

- Technical Specifications and Resource Manuals for the Adult Core Set
- Technical assistance resources for states
- · Other background information on the Adult Core Set

For more information about the Adult Core Set please contact MACQualityTA@cms.hhs.gov.

